Jan. 2024
第29回日本肝がん分子標的治療研究会, 日本肝がん分子標的治療研究会 最優秀演題Award
肝細胞癌に対するTriple therapyの基礎的Rationale～抗PD-L1, 抗VEGF, 抗CTLA-4抗体のシークエンス治療～

Nov. 2021
29th JDDW（第29回日本消化器関連学会週間）, Best Presenter Award
The effectiveness of the locoregional treatment using hepatic arterial infusion chemotherapy for locally progressed hepatocellular carcinoma

2011
久留米大学, 第13回久留米大学学術奨励賞
Metronomic S-1 chemotherapy and vandetanib: an efficacious and non-toxic treatment for hepatocellular carcinoma

Fatal portal vein thrombosis following combination therapy with atezolizumab plus bevacizumab for hepatocellular carcinoma: an autopsy case report.
Yutaro Mihara; Yu Noda; Kotaro Iemura; Miwa Sakai; Hideki Iwamoto; Reiichiro Kondo; Takashi Niizeki; Hironori Kusano; Takumi Kawaguchi; Jun Akiba
Clinical journal of gastroenterology, 01 Aug. 2025

Efficacy and safety of lenvatinib-transcatheter arterial chemoembolization sequential therapy for hepatocellular carcinoma within the up-to-seven criteria.
Shigeo Shimose; Takashi Niizeki; Hideki Iwamoto; Masatoshi Tanaka; Etsuko Moriyama; Tomotake Shirono; Masahito Nakano; Ryoko Kuromatsu; Hironori Koga; Takumi Kawaguchi
Hepatology research : the official journal of the Japan Society of Hepatology, 14 Apr. 2025

Antitumor effects and immune-mediated adverse events of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma.
Takanori Ito; Shigeo Shimose; Joji Tani; Tetsu Tomonari; Issei Saeki; Yasuto Takeuchi; Takeshi Hatanaka; Kyo Sasaki; Satoru Kakizaki; Yuki Kanayama; Naoki Yoshioka; Takehito Naito; Mamiko Takeuchi; Tetsuya Yasunaka; Masahiro Sakata; Hideki Iwamoto; Satoshi Itano; Tomotake Shirono; Norikazu Tanabe; Takafumi Yamamoto; Atsushi Naganuma; Sohji Nishina; Motoyuki Otsuka; Taro Takami; Tetsuji Takayama; Takumi Kawaguchi; Hiroki Kawashima
Hepatology research : the official journal of the Japan Society of Hepatology, Apr. 2025

The benefit of conversion therapy for patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab using newly established oncological resectability criteria in Japan.
Shigeo Shimose; Issei Saeki; Takanori Ito; Yasuto Takeuchi; Joji Tani; Tetsu Tomonari; Ryu Sasaki; Kyo Sasaki; Satoru Kakizaki; Takeshi Hatanaka; Hideki Iwamoto; Norikazu Tanabe; Takafumi Yamamoto; Atsushi Naganuma; Tomotake Shirono; Yuki Kanayama; Sohji Nishina; Tetsuji Takayama; Hideki Kobara; Motoyuki Otsuka; Hiroki Kawashima; Taro Takami; Takumi Kawaguchi
Hepatology international, 28 Feb. 2025

Hepatic arterial infusion of autologous CD34+ cells for hepatitis C virus-related decompensated cirrhosis: A multicenter, open-label, exploratory randomized controlled trial.
Toru Nakamura; Atsutaka Masuda; Makoto Kako; Hirayuki Enomoto; Masaki Kaibori; Yasuyuki Fujita; Kyoko Tanizawa; Tetsuya Ioji; Yoshihiro Fujimori; Kei Fukami; Takuma Hazama; Hideki Iwamoto; Yasukazu Kako; Kaoru Kobayashi; Hironori Koga; Koji Nagafuji; Takayasu Ohtake; Hiroyuki Suzuki; Tomoyuki Takashima; Toshitaka Tsukiyama; Haruki Uojima; Kenichi Yamahara; Koichiro Yamakado; Hidekazu Yamamoto; Kazunori Yoh; Satoshi Yoshihara; Atsuhiko Kawamoto; Shuhei Nishiguchi; Shuzo Kobayashi; Takuji Torimura; Takumi Kawaguchi
Regenerative therapy, Dec. 2024

Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study.
Mara Persano; Andrea Casadei-Gardini; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Federico Rossari; Changhoon Yoo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa; Gianluca Masi; Francesca Bergamo; Elisabeth Amadeo; Francesco Vitiello; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Massimo Alberto Iavarone; Giuseppe Cabibbo; Margarida Montes; Francesco Giuseppe Foschi; Caterina Vivaldi; Caterina Soldà; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Mariangela Bruccoleri; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Atsushi Hiraoka; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Luigi Mascia; Silvia Foti; Silvia Camera; Fabio Piscaglia; Mario Scartozzi; Stefano Cascinu; Margherita Rimini
Oncology, 11 Oct. 2024

Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study.
Federico Rossari; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Changhoon Yoo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa; Gianluca Masi; Francesca Bergamo; Elisabeth Amadeo; Francesco Vitiello; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Massimo Iavarone; Giuseppe Cabibbo; Margarida Montes; Francesco Giuseppe Foschi; Caterina Vivaldi; Caterina Soldà; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Atsushi Hiraoka; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Mara Persano; Silvia Foti; Silvia Camera; Bernardo Stefanini; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-Gardini; Margherita Rimini
Liver cancer, Oct. 2024

Efficacy of Atezolizumab Plus Bevacizumab-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma.
Etsuko Moriyama; Shigeo Shimose; Takashi Niizeki; Hideki Iwamoto; Masatoshi Tanaka; Tomotake Shirono; Yu Noda; Masahito Nakano; Ryoko Kuromatsu; Hironori Koga; Takumi Kawaguchi
Current oncology (Toronto, Ont.), 27 Sep. 2024

Dose-Reduction of Bevacizumab in Atezolizumab plus Bevacizumab Therapy Extends Treatment duration with Disease Control in Patients with Hepatocellular Carcinoma.
Miwa Sakai; Hideki Iwamoto; Shigeo Shimose; Takashi Niizeki; Masahito Nakano; Tomotake Shirono; Yu Noda; Etsuko Moriyama; Hiroyuki Suzuki; Hironori Koga; Ryoko Kuromatsu; Takumi Kawaguchi
Oncology, 12 Sep. 2024

Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab.
Margherita Rimini; Margarida Montes; Elisabeth Amadeo; Francesco Vitiello; Masatoshi Kudo; Toshifumi Tada; Goki Suda; Shigeo Shimose; Sara Lonardi; Fabian Finkelmeier; Francesca Salani; Lorenzo Antonuzzo; Fabio Marra; Massimo Iavarone; Giuseppe Cabibbo; Francesco Giuseppe Foschi; Marianna Silletta; Rodolfo Sacco; Ilario Giovanni Rapposelli; Mario Scartozzi; Pella Nicoletta; Luca Aldrighetti; Mara Persano; Silvia Camera; Federico Rossari; Silvia Foti; Takashi Kumada; Atsushi Hiraoka; Hideki Iwamoto; Mario Domenico Rizzato; Vera Himmelsbach; Gianluca Masi; Mattia Corradi; Ciro Celsa; Conti Fabio; Giovanni Luca Frassineti; Stefano Cascinu; Andrea Casadei-Gardini; Jose Presa
Scientific reports, 30 Aug. 2024

Ex-vivo expanded CD34+ cell transplantation alleviates fibrotic liver injury via innate immune modulation in metabolic dysfunction-associated steatohepatitis mice.
Atsutaka Masuda; Toru Nakamura; Hideki Iwamoto; Hiroyuki Suzuki; Takahiko Sakaue; Toshimitsu Tanaka; Yasuko Imamura; Nobuyuki Mori; Hironori Koga; Takumi Kawaguchi
Cytotherapy, Aug. 2024

Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real‑world practice.
Shigeo Shimose; Issei Saeki; Tetsu Tomonari; Takanori Ito; Joji Tani; Yasuto Takeuchi; Naoki Yoshioka; Takehito Naito; Mamiko Takeuchi; Satoru Kakizaki; Takeshi Hatanaka; Kyo Sasaki; Tetsuya Yasunaka; Masahiro Sakata; Hideki Iwamoto; Satoshi Itano; Tomotake Shirono; Norikazu Tanabe; Takafumi Yamamoto; Atsushi Naganuma; Soji Nishina; Motoyuki Otsuka; Hiroki Kawashima; Tetsuji Takayama; Taro Takami; Takumi Kawaguchi
Oncology letters, Aug. 2024

A Multidisciplinary Therapeutic Approach Proposal for Huge Hepatocellular Carcinomas Exceeding 10 cm in Diameter.
Yuichi Goto; Takashi Niizeki; Hisamune Sakai; Masanori Akashi; Shogo Fukutomi; Kazuaki Hashimoto; Hideki Iwamoto; Shigeo Shimose; Tomotake Shirono; Takefumi Yoshida; Taro Isobe; Naoki Mori; Takumi Kawaguchi; Nobuya Ishibashi; Fumihiko Fujita; Toru Hisaka
Anticancer research, Aug. 2024

Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab.
Mara Persano; Margherita Rimini; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Federico Rossari; Changhoon Yoo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa; Gianluca Masi; Francesca Bergamo; Elisabeth Amadeo; Francesco Vitiello; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Massimo Alberto Iavarone; Giuseppe Cabibbo; Margarida Montes; Francesco Giuseppe Foschi; Caterina Vivaldi; Caterina Soldà; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Mariangela Bruccoleri; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Atsushi Hiraoka; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Silvia Foti; Silvia Camera; Fabio Piscaglia; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-Gardini
Targeted oncology, Jul. 2024

Anti-PD-L1 antibodies promote cellular proliferation by activating the PD-L1-AXL signal relay in liver cancer cells.
Toshimitsu Tanaka; Hironori Koga; Hiroyuki Suzuki; Hideki Iwamoto; Takahiko Sakaue; Atsutaka Masuda; Toru Nakamura; Jun Akiba; Hirohisa Yano; Takuji Torimura; Takumi Kawaguchi
Hepatology international, Jun. 2024

Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab.
Margherita Rimini; Bernardo Stefanini; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Fabian Finkelmeier; Changhoon Yoo; José Presa; Elisabeth Amadeo; Virginia Genovesi; Maria Caterina De Grandis; Massimo Iavarone; Fabio Marra; Francesco Foschi; Emiliano Tamburini; Federico Rossari; Francesco Vitiello; Linda Bartalini; Caterina Soldà; Francesco Tovoli; Caterina Vivaldi; Sara Lonardi; Marianna Silletta; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Vera Himmelsbach; Margarida Montes; Atsushi Hiraoka; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Mara Persano; Silvia Camera; Silvia Foti; Luca Aldrighetti; Stefano Cascinu; Andrea Casadei-Gardini; Fabio Piscaglia
Liver international : official journal of the International Association for the Study of the Liver, May 2024

Fibroblast growth factor inhibition by molecular-targeted agents mitigates immunosuppressive tissue microenvironment in hepatocellular carcinoma.
Hiroyuki Suzuki; Hideki Iwamoto; Toshimitsu Tanaka; Takahiko Sakaue; Yasuko Imamura; Atsutaka Masuda; Toru Nakamura; Hironori Koga; Yujin Hoshida; Takumi Kawaguchi
Hepatology international, Apr. 2024

Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD.
Hiroyuki Suzuki; Shigeo Shimose; Hideki Iwamoto; Takashi Niizeki; Takumi Kawaguchi
Clinical and molecular hepatology, Apr. 2024

Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in Lenvatinib.
Massimo Iavarone; Eleonora Alimenti; Toshifumi Tada; Shigeo Shimose; Goki Suda; Changhoon Yoo; Caterina Soldà; Fabio Piscaglia; Giulia Tosetti; Fabio Marra; Caterina Vivaldi; Fabio Conti; Marta Schirripa; Hideki Iwamoto; Takuya Sho; So Heun Lee; Mario Domenico Rizzato; Matteo Tonnini; Margherita Rimini; Claudia Campani; Gianluca Masi; Francesco Foschi; Mariangela Bruccoleri; Takumi Kawaguchi; Takashi Kumada; Atsushi Hiraoka; Masanori Atsukawa; Shinya Fukunishi; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Takeshi Hatanaka; Satoru Kakizaki; Kazuhito Kawata; Fujimasa Tada; Hideko Ohama; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Atsushi Naganuma; Andrea Casadei-Gardini; Pietro Lampertico
Liver cancer, Apr. 2024

α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
Federico Rossari; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Changhoon Yoo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa; Gianluca Masi; Francesca Bergamo; Elisabeth Amadeo; Francesco Vitiello; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Massimo Iavarone; Giuseppe Cabibbo; Margarida Montes; Francesco Giuseppe Foschi; Caterina Vivaldi; Caterina Soldà; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Atsushi Hiraoka; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Mara Persano; Valentina Burgio; Fabio Piscaglia; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-Gardini; Margherita Rimini
International journal of cancer, 15 Mar. 2024

A tumor endothelial cell-specific microRNA replacement therapy for hepatocellular carcinoma.
Hideki Iwamoto; Hiroyuki Suzuki; Atsutaka Masuda; Takahiko Sakaue; Toru Nakamura; Toshimitsu Tanaka; Miwa Sakai; Yasuko Imamura; Hirohisa Yano; Takuji Torimura; Hironori Koga; Kaori Yasuda; Masakatsu Tsurusaki; Takahiro Seki; Takumi Kawaguchi
iScience, 16 Feb. 2024

Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma.
Silvia Camera; Margherita Rimini; Federico Rossari; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Changhoon Yoo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa; Gianluca Masi; Francesca Bergamo; Francesca Salani; Mariarosaria Marseglia; Elisabeth Amadeo; Francesco Vitiello; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Massimo Iavarone; Giuseppe Cabibbo; Margarida Montes; Francesco Giuseppe Foschi; Caterina Vivaldi; Sara Lonardi; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Atsushi Hiraoka; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Mara Persano; Silvia Foti; Fabio Piscaglia; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-Gardini
Targeted oncology, Jan. 2024

The Immune Inductive Role of Hepatic Arterial Infusion Chemotherapy Prior to Atezolizumab Plus Bevacizumab Combination Therapy in Hepatocellular Carcinoma.
Hiroyuki Suzuki; Miwa Sakai; Hideki Iwamoto; Shigeo Shimose; Takashi Niizeki; Masahito Nakano; Tomotake Shirono; Yu Noda; Etsuko Moriyama; Ryoko Kuromatsu; Hironori Koga; Takumi Kawaguchi
Gastro hep advances, 2024

Pancreatic Juice-Derived microRNA-4516 and microRNA-4674 as Novel Biomarkers for Pancreatic Ductal Adenocarcinoma.
Takahiko Sakaue; Hironori Koga; Hideki Iwamoto; Toru Nakamura; Atsutaka Masuda; Toshimitsu Tanaka; Hiroyuki Suzuki; Hideya Suga; Shingo Hirai; Toru Hisaka; Yoshiki Naito; Keisuke Ohta; Kei-Ichiro Nakamura; Karuppaiyah Selvendiran; Yoshinobu Okabe; Takuji Torimura; Takumi Kawaguchi
Gastro hep advances, 2024

Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapy.
Issei Saeki; Shigeo Shimose; Tetsu Tomonari; Takanori Ito; Joji Tani; Yasuto Takeuchi; Naoki Yoshioka; Takehito Naito; Mamiko Takeuchi; Satoru Kakizaki; Takeshi Hatanaka; Kyo Sasaki; Tetsuya Yasunaka; Masahiro Sakata; Hideki Iwamoto; Satoshi Itano; Tomotake Shirono; Norikazu Tanabe; Takafumi Yamamoto; Yuki Kanayama; Atsushi Naganuma; Sohji Nishina; Motoyuki Otsuka; Hideki Kobara; Hiroki Kawashima; Tetsuji Takayama; Takumi Kawaguchi; Takahiro Yamasaki; Taro Takami
PloS one, 2024

Preoperative Chemotherapy Followed by Hepatectomy for Potentially Resectable UICC7 Stage IIIA, IIIB Hepatocellular Carcinoma; A Phase II Clinical Trial.
Yuichi Goto; Takashi Niizeki; Shogo Fukutomi; Tomotake Shirono; Shigeo Shimose; Hideki Iwamoto; Satoki Kojima; Hiroki Kanno; Yoshihiro Uchino; Shin Sasaki; Nobuhisa Shirahama; Daisuke Muroya; Yoriko Nomura; Masanori Akashi; Goichi Nakayama; Yusuke Hirakawa; Toshihiro Sato; Munehiro Yoshitomi; Hisamune Sakai; Toru Hisaka; Tatsuyuki Kakuma; Hironori Koga; Takuji Torimura; Yoshito Akagi; Koji Okuda
The Kurume medical journal, 25 Sep. 2023

Efficacy of Lenvatinib Combined with Transcatheter Intra-Arterial Therapies for Patients with Advanced-Stage of Hepatocellular Carcinoma: A Propensity Score Matching.
Shigeo Shimose; Hideki Iwamoto; Takashi Niizeki; Masatoshi Tanaka; Tomotake Shirono; Etsuko Moriyama; Yu Noda; Masahito Nakano; Hideya Suga; Ryoko Kuromatsu; Takuji Torimura; Hironori Koga; Takumi Kawaguchi
International journal of molecular sciences, 05 Sep. 2023

Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study.
Mara Persano; Margherita Rimini; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; Lorenza Rimassa; José Presa; Gianluca Masi; Changhoon Yoo; Sara Lonardi; Francesco Tovoli; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Tiziana Pressiani; Takumi Kawaguchi; Margarida Montes; Caterina Vivaldi; Caterina Soldà; Fabio Piscaglia; Atsushi Hiraoka; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Massimo Iavarone; Giovanni Di Costanzo; Fabio Marra; Mario Scartozzi; Emiliano Tamburini; Giuseppe Cabibbo; Francesco Giuseppe Foschi; Marianna Silletta; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Antonella Cammarota; Valentina Burgio; Stefano Cascinu; Andrea Casadei-Gardini
Journal of cancer research and clinical oncology, Aug. 2023

Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients.
Margherita Rimini; Mara Persano; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa; Francesca Salani; Sara Lonardi; Fabio Piscaglia; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Marta Schirripa; Margarida Montes; Caterina Vivaldi; Caterina Soldà; Atsushi Hiraoka; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Valentina Burgio; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-Gardini
Journal of cancer research and clinical oncology, Aug. 2023

Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients.
Mara Persano; Margherita Rimini; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa; Gianluca Masi; Changhoon Yoo; Sara Lonardi; Francesco Tovoli; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Takashi Niizeki; Margarida Montes; Caterina Vivaldi; Caterina Soldà; Bernardo Stefanini; Atsushi Hiraoka; Takuya Sho; Naoshi Nishida; Christoph Steup; Massimo Iavarone; Giovanni Di Costanzo; Fabio Marra; Emiliano Tamburini; Giuseppe Cabibbo; Francesco Giuseppe Foschi; Marianna Silletta; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Claudia Campani; Elisabeth Amadeo; Federico Rossari; Valentina Burgio; Stefano Cascinu; Mario Scartozzi; Andrea Casadei-Gardini
European journal of cancer (Oxford, England : 1990), Aug. 2023

Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity.
Hideki Iwamoto; Shigeo Shimose; Tomotake Shirono; Takashi Niizeki; Takumi Kawaguchi
Clinical and molecular hepatology, Jul. 2023

Telephone follow-up contributes to improving adherence and treatment duration in patients with hepatocellular carcinoma treated with lenvatinib.
Sayo Tsumura; Shigeo Shimose; Takashi Niizeki; Eri Kuboyama; Hideki Iwamoto; Masatoshi Tanaka; Etusko Moriyama; Tomotake Shirono; Kota Takaki; Yu Noda; Masahito Nakano; Mitsutoshi Inoue; Kazuki Tsustumi; Ryoko Kuromatsu; Hironori Koga; Kyoko Higuchi; Takumi Kawaguchi
Journal of gastroenterology and hepatology, Jul. 2023

Serum osteopontin predicts the response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
Reika Yamauchi; Takanori Ito; Sachiyo Yoshio; Takafumi Yamamoto; Kazuyuki Mizuno; Masatoshi Ishigami; Hiroki Kawashima; Satoshi Yasuda; Shigeo Shimose; Hideki Iwamoto; Taiji Yamazoe; Taizo Mori; Eiji Kakazu; Takumi Kawaguchi; Hidenori Toyoda; Tatsuya Kanto
Journal of gastroenterology, Jun. 2023

The impact of curative conversion therapy aimed at a cancer-free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Shigeo Shimose; Hideki Iwamoto; Tomotake Shirono; Masatoshi Tanaka; Takashi Niizeki; Masahiko Kajiwara; Satoshi Itano; Yoichi Yano; Satoru Matsugaki; Etsuko Moriyama; Yu Noda; Masahito Nakano; Ryoko Kuromatsu; Hironori Koga; Takumi Kawaguchi
Cancer medicine, Jun. 2023

Safety of Early Bevacizumab Administration after Central Venous Port Placement for Patients with Colorectal Cancer.
Hirona Shigyo; Hiroyuki Suzuki; Toshimitsu Tanaka; Etsuko Moriyama; Yasutaka Shimotsuura; Sachiko Nagasu; Hideki Iwamoto; Yoshito Akagi; Kenta Murotani; Takumi Kawaguchi; Keisuke Miwa
Cancers, 12 Apr. 2023

Tumor-derived insulin-like growth factor-binding protein-1 contributes to resistance of hepatocellular carcinoma to tyrosine kinase inhibitors.
Hiroyuki Suzuki; Hideki Iwamoto; Takahiro Seki; Toru Nakamura; Atsutaka Masuda; Takahiko Sakaue; Toshimitsu Tanaka; Yasuko Imamura; Takashi Niizeki; Masahito Nakano; Shigeo Shimose; Tomotake Shirono; Yu Noda; Naoki Kamachi; Miwa Sakai; Kazutoyo Morita; Masamichi Nakayama; Tomoharu Yoshizumi; Ryoko Kuromatsu; Hirohisa Yano; Yihai Cao; Hironori Koga; Takuji Torimura
Cancer communications (London, England), Apr. 2023

Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective.
Hironori Koga; Hideki Iwamoto; Hiroyuki Suzuki; Shigeo Shimose; Masahito Nakano; Takumi Kawaguchi
Clinical and molecular hepatology, Apr. 2023

Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?
Margherita Rimini; Mara Persano; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa; Gianluca Masi; Changhoon Yoo; Sara Lonardi; Fabio Piscaglia; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Tiziana Pressiani; Margarida Montes; Caterina Vivaldi; Caterina Soldà; Atsushi Hiraoka; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Valentina Burgio; Lorenza Rimassa; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-Gardini
Targeted oncology, Mar. 2023

The beneficial impact of metabolic dysfunction-associated fatty liver disease on lenvatinib treatment in patients with non-viral hepatocellular carcinoma.
Shigeo Shimose; Atsushi Hiraoka; Andrea Casadei-Gardini; Tsubasa Tsutsumi; Dan Nakano; Hideki Iwamoto; Fujimasa Tada; Margherita Rimini; Masatoshi Tanaka; Takuji Torimura; Hideya Suga; Hideko Ohama; Valentina Burgio; Takashi Niizeki; Etsuko Moriyama; Hiroyuki Suzuki; Tomotake Shirono; Yu Noda; Naoki Kamachi; Masahito Nakano; Ryoko Kuromatsu; Hironori Koga; Takumi Kawaguchi
Hepatology research : the official journal of the Japan Society of Hepatology, Feb. 2023

Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real-world data.
Shigeo Shimose; Rie Sugimoto; Atsushi Hiraoka; Masatoshi Tanaka; Hideki Iwamoto; Yuki Tanaka; Fujimasa Tada; Hideko Ohama; Takashi Niizeki; Tomotake Shirono; Etsuko Moriyama; Yu Noda; Naoki Kamachi; Masahito Nakano; Ryoko Kuromatsu; Hironori Koga; Takumi Kawaguchi
Hepatology research : the official journal of the Japan Society of Hepatology, Feb. 2023

Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population.
Andrea Casadei-Gardini; Margherita Rimini; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; Lorenza Rimassa; José Presa; Gianluca Masi; Changhoon Yoo; Sara Lonardi; Francesco Tovoli; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Tiziana Pressiani; Margarida Montes; Caterina Vivaldi; Caterina Soldà; Fabio Piscaglia; Atsushi Hiraoka; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Massimo Iavarone; Giovanni Di Costanzo; Fabio Marra; Mario Scartozzi; Emiliano Tamburini; Giuseppe Cabibbo; Francesco Giuseppe Foschi; Marianna Silletta; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Valentina Burgio; Mara Persano; Angelo Della Corte; Francesca Ratti; Francesco De Cobelli; Luca Aldrighetti; Stefano Cascinu; Alessandro Cucchetti
European journal of cancer (Oxford, England : 1990), Feb. 2023

Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab.
Mara Persano; Margherita Rimini; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa; Gianluca Masi; Changhoon Yoo; Sara Lonardi; Bernardo Stefanini; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Margarida Montes; Caterina Vivaldi; Caterina Soldà; Atsushi Hiraoka; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Valentina Burgio; Angelo Della Corte; Francesca Ratti; Francesco De Cobelli; Luca Aldrighetti; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-Gardini
Oncology, 2023

[A case of difficult treatment of infected pseudoaneurysm of the femoral artery during hepatic arterial infusion chemotherapy for hepatocellular carcinoma].
Hiroyuki Suzuki; Tomotake Shirono; Takashi Niizeki; Hideki Iwamoto; Shigeo Shimose; Yu Noda; Koji Nakao; Shoutarou Yamaguchi; Ken Miyazaki; Takumi Kawaguchi
Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2023

Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib.
Margherita Rimini; Wonseok Kang; Valentina Burgio; Mara Persano; Tamoko Aoki; Shigeo Shimose; Toshifumi Tada; Takashi Kumada; Takuya Sho; Eleonora Lai; Ciro Celsa; Claudia Campani; Matteo Tonnini; Emiliano Tamburini; Atsushi Hiraoka; Koichi Takaguchi; Naoshi Nishida; Hideki Iwamoto; Ei Itobayashi; Kunihiko Tsuji; Naoya Sakamoto; Toru Ishikawa; Hidenori Toyoda; Masatoshi Kudo; Takumi Kawaguchi; Takeshi Hatanaka; Kazugiro Nouso; Goki Suda; Giuseppe Cabibbo; Fabio Marra; Angelo Della Corte; Francesca Ratti; Federica Pedica; Francesco De Cobelli; Luca Aldrighetti; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-Gardini
Hepatology research : the official journal of the Japan Society of Hepatology, Dec. 2022

Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study.
Andrea Casadei-Gardini; Margherita Rimini; Masatoshi Kudo; Shigeo Shimose; Toshifumi Tada; Goki Suda; Myung Ji Goh; Andre Jefremow; Mario Scartozzi; Giuseppe Cabibbo; Claudia Campani; Emiliano Tamburini; Francesco Tovoli; Kazuomi Ueshima; Tomoko Aoki; Hideki Iwamoto; Takuji Torimura; Takashi Kumada; Atsushi Hiraoka; Masanori Atsukawa; Ei Itobayashi; Hidenori Toyoda; Naoya Sakamoto; Takuya Sho; Wonseok Kang; Jürgen Siebler; Markus Friedrich Neurath; Valentina Burgio; Stefano Cascinu
Liver cancer, Dec. 2022

Deterioration of liver function and aging disturb sequential systemic therapy for unresectable hepatocellular carcinoma.
Shigeo Shimose; Atsushi Hiraoka; Masatoshi Tanaka; Hideki Iwamoto; Takaaki Tanaka; Kazunori Noguchi; Hajime Aino; Taizo Yamaguchi; Satoshi Itano; Hideya Suga; Takashi Niizeki; Etsuko Moriyama; Tomotake Shirono; Yu Noda; Naoki Kamachi; Shusuke Okamura; Masahito Nakano; Takumi Kawaguchi; Ryoko Kuromatsu; Hironori Koga; Takuji Torimura
Scientific reports, 11 Oct. 2022

The Clinical Impact of Hepatic Arterial Infusion Chemotherapy New-FP for Hepatocellular Carcinoma with Preserved Liver Function.
Hideki Iwamoto; Takashi Niizeki; Hiroaki Nagamatsu; Kazuomi Ueshima; Joji Tani; Teiji Kuzuya; Kazuhiro Kasai; Youhei Kooka; Atsushi Hiraoka; Rie Sugimoto; Takehiro Yonezawa; Satoshi Tanaka; Akihiro Deguchi; Shigeo Shimose; Tomotake Shirono; Miwa Sakai; Hiroyuki Suzuki; Etsuko Moriyama; Hironori Koga; Takuji Torimura; Takumi Kawaguchi; New Fp Study Group; Kurume Liver Cancer Study Group Of Japan
Cancers, 05 Oct. 2022

Durable complete response is achieved by balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma.
Tomotake Shirono; Hideki Iwamoto; Takashi Niizeki; Shigeo Shimose; Akira Kajiwara; Hiroyuki Suzuki; Naoki Kamachi; Yu Noda; Shusuke Okamura; Masahito Nakano; Ryoko Kuromatsu; Kenta Murotani; Hironori Koga; Takuji Torimura
Hepatology communications, Sep. 2022

Hyperlipidemia as a risk factor for Trousseau syndrome-related cerebral infarction in patients with advanced gastrointestinal cancer.
Toshimitsu Tanaka; Hiroyuki Suzuki; Keisuke Miwa; Tomoyuki Ushijima; Sachiko Nagasu; Masaru Fukahori; Kaito Ishii; Toru Nakamura; Hideki Iwamoto; Atsutaka Masuda; Takahiko Sakaue; Hironori Koga; Yoshito Akagi; Kenta Murotani; Takuji Torimura
Oncology letters, Sep. 2022

Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study.
Shigeo Shimose; Hideki Iwamoto; Masatoshi Tanaka; Takashi Niizeki; Masahiko Kajiwara; Satoshi Itano; Etsuko Moriyama; Tomotake Shirono; Yu Noda; Naoki Kamachi; Masahito Nakano; Ryoko Kuromatsu; Hironori Koga; Takumi Kawaguchi
Cancers, 01 Sep. 2022

Clinical Practice Guidelines for Hepatic Arterial Infusion Chemotherapy with a Port System Proposed by the Japanese Society of Interventional Radiology and Japanese Society of Implantable Port Assisted Treatment.
Kazuomi Ueshima; Atsushi Komemushi; Takeshi Aramaki; Hideki Iwamoto; Shuntaro Obi; Yozo Sato; Toshihiro Tanaka; Kiyoshi Matsueda; Michihisa Moriguchi; Hiroya Saito; Miyuki Sone; Takuji Yamagami; Yoshitaka Inaba; Masatoshi Kudo; Yasuaki Arai
Liver cancer, Sep. 2022

Usefulness of a novel transarterial chemoinfusion plus external-beam radiation therapy for advanced hepatocellular carcinoma with tumor thrombi in the inferior vena cava and right atrium: Case study.
Tomotake Shirono; Hironori Koga; Takashi Niizeki; Hiroaki Nagamatsu; Hideki Iwamoto; Shigeo Shimose; Masahito Nakano; Shusuke Okamura; Yu Noda; Naoki Kamachi; Ryoko Kuromatsu; Etsuyo Ogo; Takuji Torimura
Cancer reports (Hoboken, N.J.), Aug. 2022

Treatment and the prognosis of hepatocellular carcinoma in Asia.
Takuji Torimura; Hideki Iwamoto
Liver international : official journal of the International Association for the Study of the Liver, Aug. 2022

Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma.
Hideki Iwamoto; Shigeo Shimose; Takashi Niizeki; Hironori Koga; Takuji Torimura
Clinical and molecular hepatology, Jul. 2022

Hepatitis C Virus Elimination Using Direct Acting Antivirals after the Radical Cure of Hepatocellular Carcinoma Suppresses the Recurrence of the Cancer.
Ryoko Kuromatsu; Tatsuya Ide; Shusuke Okamura; Yu Noda; Naoki Kamachi; Masahito Nakano; Tomotake Shirono; Shigeo Shimose; Hideki Iwamoto; Reiichiro Kuwahara; Teruko Arinaga-Hino; Takashi Niizeki; Yuki Zaizen; Hiroshi Takaki; Miki Shirachi; Hironori Koga; Takuji Torimura
Cancers, 04 May 2022

Robust Effect of Hepatic Arterial Infusion Chemotherapy and Radiation Therapy on Hepatocellular Carcinoma Arising from Fontan-associated Liver Disease.
Hiroyuki Suzuki; Takashi Niizeki; Tomotake Shirono; Yusuke Koteda; Yoshinao Kinjyo; Naohisa Mizukami; Makoto Koda; Satoshi Ota; Masahito Nakano; Shusuke Okamura; Hideki Iwamoto; Shigeo Shimose; Yu Noda; Naoki Kamachi; Akira Kajiwara; Kenji Suda; Jun Akiba; Hirohisa Yano; Ryoko Kuromatsu; Hironori Koga; Takuji Torimura
Internal medicine (Tokyo, Japan), 15 Apr. 2022

抗PD-L1抗体による肝癌細胞増殖機構の解明
田中 俊光; 古賀 浩徳; 鈴木 浩之; 岩本 英希; 阪上 尊彦; 増田 篤高; 中村 徹; 秋葉 純; 矢野 博久; 鳥村 拓司
日本消化器病学会雑誌, Mar. 2022

Feasibility and safety of a novel indwelling catheter system via the femoral artery for intermittent transarterial therapy for treating malignant liver tumors.
Hideki Iwamoto; Satoshi Itano; Osamu Itano; Masatsugu Ishii; Takashi Niizeki; Tomotake Shirono; Shigeo Shimose; Hiroyuki Suzuki; Akira Kajiwara; Taizo Yamaguchi; Hironori Koga; Takuji Torimura
Japanese journal of radiology, Mar. 2022

Evaluating the therapeutic effect of lenvatinib against advanced hepatocellular carcinoma by measuring blood flow changes using contrast-enhanced ultrasound.
Naoki Kamachi; Masahito Nakano; Shusuke Okamura; Takashi Niizeki; Hideki Iwamoto; Shigeo Shimose; Tomotake Shirono; Yu Noda; Ryoko Kuromatsu; Hironori Koga; Takuji Torimura
Cancer reports (Hoboken, N.J.), Feb. 2022

Association between contrast enhancement on contrast-enhanced CT and lenvatinib effectiveness in hepatocellular carcinoma.
Shusuke Okamura; Shigeo Shimose; Takashi Niizeki; Naoki Kamachi; Yu Noda; Tomotake Shirono; Hideki Iwamoto; Masahito Nakano; Ryoko Kuromatsu; Hironori Koga; Takuji Torimura
Molecular and clinical oncology, Jan. 2022

Efficacy and Safety of Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma and Child-Pugh Class B: A Retrospective Cohort Study.
Masatsugu Ishii; Osamu Itano; Hideki Iwamoto; Taizo Hibi; Satoshi Itano
Oncology, 2022

DNA Methylation in Noncancerous Liver Tissues as Biomarker for Multicentric Occurrence of Hepatitis C Virus-Related Hepatocellular Carcinoma.
Hiroyuki Suzuki; Hideki Iwamoto; Ken Yamamoto; Mai Tsukaguchi; Toru Nakamura; Atsutaka Masuda; Takahiko Sakaue; Toshimitsu Tanaka; Takashi Niizeki; Shusuke Okamura; Shigeo Shimose; Tomotake Shirono; Yu Noda; Naoki Kamachi; Ryoko Kuromatsu; Toru Hisaka; Hirohisa Yano; Hironori Koga; Takuji Torimura
Gastro hep advances, 2022

Case Report: Exacerbation of varices following atezolizumab plus bevacizumab treatment of hepatocellular carcinoma: A case series and literature review.
Hiroyuki Suzuki; Hideki Iwamoto; Shigeo Shimose; Takashi Niizeki; Tomotake Shirono; Yu Noda; Naoki Kamachi; Taizo Yamaguchi; Masahito Nakano; Ryoko Kuromatsu; Hironori Koga; Takumi Kawaguchi
Frontiers in oncology, 2022

Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib.
Ilario Giovanni Rapposelli; Toshifumi Tada; Shigeo Shimose; Valentina Burgio; Takashi Kumada; Hideki Iwamoto; Atsushi Hiraoka; Takashi Niizeki; Masanori Atsukawa; Hironori Koga; Masashi Hirooka; Takuji Torimura; Massimo Iavarone; Raffaella Tortora; Claudia Campani; Sara Lonardi; Emiliano Tamburini; Fabio Piscaglia; Gianluca Masi; Giuseppe Cabibbo; Francesco Giuseppe Foschi; Marianna Silletta; Kunihiko Tsuji; Toru Ishikawa; Koichi Takaguchi; Kazuya Kariyama; Ei Itobayashi; Kazuto Tajiri; Noritomo Shimada; Hiroshi Shibata; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Shinya Fukunishi; Hideko Ohama; Kazuhito Kawata; Joji Tani; Shinichiro Nakamura; Kazuhiro Nouso; Akemi Tsutsui; Takuya Nagano; Takaaki Tanaka; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Kouji Joko; Yohei Koizumi; Yoichi Hiasa; Margherita Rimini; Francesca Ratti; Luca Aldrighetti; Stefano Cascinu; Andrea Casadei-Gardini
Liver international : official journal of the International Association for the Study of the Liver, Dec. 2021

Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study.
Margherita Rimini; Shigeo Shimose; Sara Lonardi; Toshifumi Tada; Gianluca Masi; Hideki Iwamoto; Eleonora Lai; Valentina Burgio; Atsushi Hiraoka; Toru Ishikawa; Caterina Soldà; Tomotake Shirono; Caterina Vivaldi; Koichi Takaguchi; Noritomo Shimada; Giorgio Astara; Hironori Koga; Kazuhiro Nouso; Kouji Joko; Takuji Torimura; Yoichi Hiasa; Francesca Salani; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-Gardini
Hepatology research : the official journal of the Japan Society of Hepatology, Dec. 2021

First-line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study.
Shigeo Shimose; Atsushi Hiraoka; Masahito Nakano; Hideki Iwamoto; Masatoshi Tanaka; Takaaki Tanaka; Kazunori Noguchi; Hajime Aino; Kei Ogata; Masahiko Kajiwara; Satoshi Itano; Yoshinori Yokokura; Taizo Yamaguchi; Hiroshi Kawano; Norito Matsukuma; Hideya Suga; Takashi Niizeki; Tomotake Shirono; Yu Noda; Naoki Kamachi; Shusuke Okamura; Takumi Kawaguchi; Hironori Koga; Takuji Torimura
Cancer medicine, Dec. 2021

Efficacy and tolerability of Sorafenib plus metronomic chemotherapy S-1 for advanced hepatocellular carcinoma in preclinical and clinical assessments.
Hiroyuki Suzuki; Hideki Iwamoto; Masahito Nakano; Toru Nakamura; Atsutaka Masuda; Takahiko Sakaue; Toshimitsu Tanaka; Dan Nakano; Ryoko Kuromatsu; Takashi Niizeki; Shusuke Okamura; Shigeo Shimose; Tomotake Shirono; Yu Noda; Naoki Kamachi; Hirohisa Yano; Atsushi Kawaguchi; Hironori Koga; Takuji Torimura
Translational oncology, Nov. 2021

Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis.
Yuki Zaizen; Masahito Nakano; Kazuta Fukumori; Yoichi Yano; Kota Takaki; Takashi Niizeki; Kotaro Kuwaki; Masaru Fukahori; Takahiko Sakaue; Sohei Yoshimura; Mika Nakazaki; Ryoko Kuromatsu; Shusuke Okamura; Hideki Iwamoto; Shigeo Shimose; Tomotake Shirono; Yu Noda; Naoki Kamachi; Hironori Koga; Takuji Torimura
Cancers, 21 Oct. 2021

Clinical Importance of Regimens in Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Macrovascular Invasion.
Takashi Niizeki; Hideki Iwamoto; Tomotake Shirono; Shigeo Shimose; Masahito Nakano; Shusuke Okamura; Yu Noda; Naoki Kamachi; Suzuki Hiroyuki; Miwa Sakai; Ryoko Kuromatsu; Hironori Koga; Takuji Torimura
Cancers, 03 Sep. 2021

Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice.
Hideki Iwamoto; Shigeo Shimose; Yu Noda; Tomotake Shirono; Takashi Niizeki; Masahito Nakano; Shusuke Okamura; Naoki Kamachi; Hiroyuki Suzuki; Miwa Sakai; Akira Kajiwara; Satoshi Itano; Masatoshi Tanaka; Taizo Yamaguchi; Ryoko Kuromatsu; Hironori Koga; Takuji Torimura; On Behalf Of The Kurume Liver Cancer Study Group Of Japan
Cancers, 03 Jun. 2021

Efficacy of a Glass Membrane Emulsification Device to Form Mixture of Cisplatin Powder with Lipiodol on Transarterial Therapy for Hepatocellular Carcinoma.
Toshihiro Tanaka; Hideki Iwamoto; Mitsuteru Fujihara; Hideyuki Nishiofuku; Tetsuya Masada; Hiroyuki Suzuki; Hironori Koga; Takuji Torimura; Kimihiko Kichikawa
Cardiovascular and interventional radiology, May 2021

QOL改善を目指した自家末梢血CD34陽性細胞移植による肝硬変治療開発　　　　　　　　　　　　　　　
中村 徹; 増田 篤高; 岩本 英希; 鈴木 浩之; 田中 俊光; 阪上 尊彦; 古賀 浩徳; 鳥村 拓司
肝臓, Apr. 2021

Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects.
Takuji Torimura; Hideki Iwamoto
Clinical and molecular hepatology, Apr. 2021

Prevalence and profiles of ramucirumab-associated severe ascites in patients with hepatocellular carcinoma.
Naoki Kamachi; Shigeo Shimose; Keisuke Hirota; Shunji Koya; Hideki Iwamoto; Takashi Niizeki; Tomotake Shirono; Masahito Nakano; Ryuki Hashida; Takumi Kawaguchi; Hiroo Matuse; Kazunori Noguchi; Hironori Koga; Takuji Torimura
Molecular and clinical oncology, Apr. 2021

Therapeutic Outcomes and Prognostic Factors of Unresectable Intrahepatic Cholangiocarcinoma: A Data Mining Analysis.
Tomotake Shirono; Takashi Niizeki; Hideki Iwamoto; Shigeo Shimose; Hiroyuki Suzuki; Takumi Kawaguchi; Naoki Kamachi; Yu Noda; Shusuke Okamura; Masahito Nakano; Ryoko Kuromatu; Hironori Koga; Takuji Torimura
Journal of clinical medicine, 02 Mar. 2021

Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma.
Hideki Iwamoto; Takashi Niizeki; Hiroaki Nagamatsu; Kazuomi Ueshima; Takako Nomura; Teiji Kuzuya; Kazuhiro Kasai; Yohei Kooka; Atsushi Hiraoka; Rie Sugimoto; Takehiro Yonezawa; Akio Ishihara; Akihiro Deguchi; Hirotaka Arai; Shigeo Shimose; Tomotake Shirono; Masahito Nakano; Shusuke Okamura; Yu Noda; Naoki Kamachi; Miwa Sakai; Hiroyuki Suzuki; Hajime Aino; Norito Matsukuma; Satoru Matsugaki; Kei Ogata; Yoichi Yano; Takato Ueno; Masahiko Kajiwara; Satoshi Itano; Kunitaka Fukuizumi; Hiroshi Kawano; Kazunori Noguchi; Masatoshi Tanaka; Taizo Yamaguchi; Ryoko Kuromatsu; Atsushi Kawaguchi; Hironori Koga; Takuji Torimura; New Fp Study Group; Kurume Liver Cancer Study Group Of Japan
Cancers, 05 Feb. 2021

Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study.
Shigeo Shimose; Hideki Iwamoto; Masatoshi Tanaka; Takashi Niizeki; Tomotake Shirono; Yu Noda; Naoki Kamachi; Shusuke Okamura; Masahito Nakano; Hideya Suga; Taizo Yamaguchi; Takumi Kawaguchi; Ryoko Kuromatsu; Kazunori Noguchi; Hironori Koga; Takuji Torimura
Cancers, 05 Jan. 2021

Multimolecular-Targeted Agents for Intermediate-Stage Hepatocellular Carcinoma Influence Time to Stage Progression and Overall Survival.
Shigeo Shimose; Hideki Iwamoto; Masatoshi Tanaka; Takashi Niizeki; Tomotake Shirono; Akira Kajiwara; Yu Noda; Naoki Kamachi; Shusuke Okamura; Masahito Nakano; Ryoko Kuromatsu; Takumi Kawaguchi; Hironori Koga; Takuji Torimura
Oncology, 2021

レンバチニブ投与により上昇する血清IGFBP-1は腫瘍内虚血を反映する　　　　　　　　　　　　　　　
鈴木 浩之; 岩本 英希; 阪上 尊彦; 田中 俊光; 古賀 浩徳; 鳥村 拓司
日本癌学会総会記事, Oct. 2020

Correction: Ablation of endothelial VEGFR1 improves metabolic dysfunction by inducing adipose tissue browning.
Takahiro Seki; Kayoko Hosaka; Carina Fischer; Sharon Lim; Patrik Andersson; Mitsuhiko Abe; Hideki Iwamoto; Yanyan Gao; Xinsheng Wang; Guo-Hua Fong; Yihai Cao
The Journal of experimental medicine, 07 Sep. 2020

Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis.
Shigeo Shimose; Takumi Kawaguchi; Masatoshi Tanaka; Hideki Iwamoto; Ken Miyazaki; Etsuko Moriyama; Hiroyuki Suzuki; Takashi Niizeki; Tomotake Shirono; Masahito Nakano; Hideya Suga; Taizo Yamaguchi; Yoshinori Yokokura; Kazunori Noguchi; Hironori Koga; Takuji Torimura
Oncology letters, Sep. 2020

Primary Treatment with Molecular-Targeted Agents for Hepatocellular Carcinoma: A Propensity Score-matching Analysis.
Masahito Nakano; Ryoko Kuromatsu; Takashi Niizeki; Shusuke Okamura; Hideki Iwamoto; Shigeo Shimose; Tomotake Shirono; Yu Noda; Naoki Kamachi; Hironori Koga; Takuji Torimura
Hepatology communications, Aug. 2020

Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study.
Shigeo Shimose; Hideki Iwamoto; Takashi Niizeki; Tomotake Shirono; Yu Noda; Naoki Kamachi; Shusuke Okamura; Masahito Nakano; Hideya Suga; Ryoko Kuromatsu; Taizo Yamaguchi; Takumi Kawaguchi; Masatoshi Tanaka; Kazunori Noguchi; Hironori Koga; Takuji Torimura
Cancers, 11 Jul. 2020

Promotion of liver regeneration and anti‑fibrotic effects of the TGF‑β receptor kinase inhibitor galunisertib in CCl4‑treated mice.
Atsutaka Masuda; Toru Nakamura; Mitsuhiko Abe; Hideki Iwamoto; Takahiko Sakaue; Toshimitsu Tanaka; Hiroyuki Suzuki; Hironori Koga; Takuji Torimura
International journal of molecular medicine, Jul. 2020

Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability toward Adverse Events.
Hideki Iwamoto; Hiroyuki Suzuki; Shigeo Shimose; Takashi Niizeki; Masahito Nakano; Tomotake Shirono; Shusuke Okamura; Yu Noda; Naoki Kamachi; Toru Nakamura; Atsutaka Masuda; Takahiko Sakaue; Toshimitsu Tanaka; Dan Nakano; Miwa Sakai; Taizo Yamaguchi; Ryoko Kuromatsu; Hironori Koga; Takuji Torimura
Cancers, 19 Apr. 2020

Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Cohort Study.
Shigeo Shimose; Takumi Kawaguchi; Hideki Iwamoto; Masatoshi Tanaka; Ken Miyazaki; Miki Ono; Takashi Niizeki; Tomotake Shirono; Shusuke Okamura; Masahito Nakano; Hideya Suga; Taizo Yamaguchi; Yoshinori Yokokura; Kazunori Noguchi; Hironori Koga; Takuji Torimura
Nutrients, 13 Apr. 2020

レンバチニブは腫瘍免疫微小環境を免疫学的'cold'から'hot'へ変化させる　　　　　　　　　　　　　　　
鈴木 浩之; 岩本 英希; 中村 徹; 増田 篤高; 阪上 尊彦; 田中 俊光; 中野 暖; 古賀 浩徳; 鳥村 拓司
肝臓, Apr. 2020

Indication of suitable transarterial chemoembolization and multikinase inhibitors for intermediate stage hepatocellular carcinoma.
Shigeo Shimose; Takumi Kawaguchi; Hideki Iwamoto; Takashi Niizeki; Tomotake Shirono; Masatoshi Tanaka; Hironori Koga; Takuji Torimura
Oncology letters, Apr. 2020

Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: Multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT).
Dan Nakano; Takumi Kawaguchi; Hideki Iwamoto; Masako Hayakawa; Hironori Koga; Takuji Torimura
PloS one, 2020

Increased Arterio-Portal Shunt Formation after Drug-Eluting Beads TACE for Hepatocellular Carcinoma.
Shigeo Shimose; Hideki Iwamoto; Masatoshi Tanaka; Takashi Niizeki; Tomotake Shirono; Masahito Nakano; Syusuke Okamura; Yu Noda; Naoki Kamachi; Miwa Sakai; Hiroyuki Suzuki; Mika Nomiyama; Ryoko Kuromatsu; Hironori Koga; Takuji Torimura
Oncology, 2020

Glycosylation of ascites-derived exosomal CD133: a potential prognostic biomarker in patients with advanced pancreatic cancer.
Takahiko Sakaue; Hironori Koga; Hideki Iwamoto; Toru Nakamura; Yu Ikezono; Mitsuhiko Abe; Fumitaka Wada; Atsutaka Masuda; Toshimitsu Tanaka; Masaru Fukahori; Tomoyuki Ushijima; Yuutarou Mihara; Yoshiki Naitou; Yoshinobu Okabe; Tatsuyuki Kakuma; Keisuke Ohta; Kei-Ichiro Nakamura; Takuji Torimura
Medical molecular morphology, Dec. 2019

肝癌細胞におけるClaudin-2のWntシグナルに対する2面的効果(Two-faced effects of Claudin-2 on Wnt signaling in liver cancer cells)　　　　　　　　　　　　　　　
古賀 浩徳; 岩本 英希; 阪上 尊彦; 鳥村 拓司
日本癌学会総会記事, Sep. 2019

Prognostic impact of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation in patients with unresectable hepatocellular carcinoma: Comparison with TACE alone using decision-tree analysis after propensity score matching.
Shigeo Shimose; Masatoshi Tanaka; Hideki Iwamoto; Takashi Niizeki; Tomotake Shirono; Hajime Aino; Yu Noda; Naoki Kamachi; Shusuke Okamura; Masahito Nakano; Ryoko Kuromatsu; Takumi Kawaguchi; Atsushi Kawaguchi; Hironori Koga; Yoshinori Yokokura; Takuji Torimura
Hepatology research : the official journal of the Japan Society of Hepatology, Aug. 2019

Epirubicin is More Effective than Miriplatin in Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma.
Tomotake Shirono; Hideki Iwamoto; Takashi Niizeki; Shigeo Shimose; Masahito Nakano; Manabu Satani; Syuusuke Okamura; Yu Noda; Naoki Kamachi; Ryoko Kuromatsu; Miwa Sakai; Mika Nomiyama; Toru Kuwano; Masatoshi Tanaka; Hironori Koga; Takuji Torimura
Oncology, 2019

Dose and Location of Irradiation Determine Survival for Patients with Hepatocellular Carcinoma with Macrovascular Invasion in External Beam Radiation Therapy.
Hideki Iwamoto; Mika Nomiyama; Takashi Niizeki; Shigeo Shimose; Tomotake Shirono; Masahito Nakano; Manabu Satani; Syusuke Okamura; Yu Noda; Naoki Kamachi; Miwa Sakai; Hiroyuki Suzuki; Ryoko Kuromatsu; Etsuyo Ogo; Toshi Abe; Masatoshi Tanaka; Hironori Koga; Takuji Torimura
Oncology, 2019

癌性腹水由来exosome中CD133に対する糖鎖修飾が進行膵癌患者の予後予測のバイオマーカーとなり得る　　　　　　　　　　　　　　　
阪上 尊彦; 古賀 浩徳; 岩本 英希; 中村 徹; 安倍 満彦; 和田 史孝; 増田 篤高; 田中 俊光; 深堀 理; 牛島 知之; 岡部 義信; 鳥村 拓司
日本消化器病学会雑誌, Oct. 2018

Claudin-2は,肝癌細胞においてLKB1-AMPKシグナル系を活性化し細胞周期停止およびオートファジーを誘導する(Claudin-2 activates LKB1-AMPK signals, thereby inducing cell-cycle arrest and autophagy in liver cancer cells)　　　　　　　　　　　　　　　
古賀 浩徳; 和田 史孝; 阪上 尊彦; 岩本 英希; 安倍 満彦; 鳥村 拓司
日本癌学会総会記事, Sep. 2018

High expression of CD44v9 and xCT in chemoresistant hepatocellular carcinoma: Potential targets by sulfasalazine.
Fumitaka Wada; Hironori Koga; Jun Akiba; Takashi Niizeki; Hideki Iwamoto; Yu Ikezono; Toru Nakamura; Mitsuhiko Abe; Atsutaka Masuda; Takahiko Sakaue; Toshimitsu Tanaka; Tatsuyuki Kakuma; Hirohisa Yano; Takuji Torimura
Cancer science, Sep. 2018

Cancer Lipid Metabolism Confers Antiangiogenic Drug Resistance.
Hideki Iwamoto; Mitsuhiko Abe; Yunlong Yang; Dongmei Cui; Takahiro Seki; Masaki Nakamura; Kayoko Hosaka; Sharon Lim; Jieyu Wu; Xingkang He; Xiaoting Sun; Yongtian Lu; Qingjun Zhou; Weiyun Shi; Takuji Torimura; Guohui Nie; Qi Li; Yihai Cao
Cell metabolism, 03 Jul. 2018

Ablation of endothelial VEGFR1 improves metabolic dysfunction by inducing adipose tissue browning.
Takahiro Seki; Kayoko Hosaka; Carina Fischer; Sharon Lim; Patrik Andersson; Mitsuhiko Abe; Hideki Iwamoto; Yanyan Gao; Xinsheng Wang; Guo-Hua Fong; Yihai Cao
The Journal of experimental medicine, 05 Feb. 2018

Clinical effects and safety of intra-arterial infusion therapy of cisplatin suspension in lipiodol combined with 5-fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extra-hepatic spread: A prospective cohort study.
Masahito Nakano; Takashi Niizeki; Hiroaki Nagamatsu; Masatoshi Tanaka; Ryoko Kuromatsu; Manabu Satani; Shusuke Okamura; Hideki Iwamoto; Shigeo Shimose; Tomotake Shirono; Yu Noda; Hironori Koga; Takuji Torimura
Molecular and clinical oncology, Dec. 2017

Off-tumor targets compromise antiangiogenic drug sensitivity by inducing kidney erythropoietin production.
Masaki Nakamura; Yin Zhang; Yunlong Yang; Ceylan Sonmez; Wenyi Zheng; Guichun Huang; Takahiro Seki; Hideki Iwamoto; Bo Ding; Linlin Yin; Theodoros Foukakis; Thomas Hatschek; Xuri Li; Kayoko Hosaka; Jiaping Li; Guohua Yu; Xinsheng Wang; Yizhi Liu; Yihai Cao
Proceedings of the National Academy of Sciences of the United States of America, 07 Nov. 2017

STAT3 deficiency prevents hepatocarcinogenesis and promotes biliary proliferation in thioacetamide-induced liver injury.
Mitsuhiko Abe; Takafumi Yoshida; Jun Akiba; Yu Ikezono; Fumitaka Wada; Atsutaka Masuda; Takahiko Sakaue; Toshimitsu Tanaka; Hideki Iwamoto; Toru Nakamura; Michio Sata; Hironori Koga; Akihiko Yoshimura; Takuji Torimura
World journal of gastroenterology, 07 Oct. 2017

肝動注化学塞栓療法後に残存した肝細胞癌におけるCD44v9の発現の検討　　　　　　　　　　　　　　　
和田 史孝; 古賀 浩徳; 秋葉 純; 池園 友; 中村 徹; 安倍 満彦; 岩本 英希; 阪上 尊彦; 増田 篤高; 田中 俊光; 矢野 博久; 鳥村 拓司
日本癌学会総会記事, Sep. 2017

HES1はWNTシグナル改変肝癌細胞においてスフィア形成能や造腫瘍能を決定的に制御する　　　　　　　　　　　　　　　
古賀 浩徳; 中村 徹; 和田 史孝; 岩本 英希; 増田 篤高; 阪上 尊彦; 田中 俊光; 安倍 満彦; 秋葉 純; 矢野 博久; 鳥村 拓司
日本癌学会総会記事, Sep. 2017

膵癌癌性腹水由来エクソソームに内在するCD133糖鎖の臨床的意義　　　　　　　　　　　　　　　
阪上 尊彦; 古賀 浩徳; 中村 徹; 池園 友; 和田 史孝; 安倍 満彦; 岩本 英希; 増田 篤高; 田中 俊光; 深堀 理; 岡部 義信; 鳥村 拓司
日本消化器病学会雑誌, Sep. 2017

Pancreatic Neuroendocrine Tumors and EMT Behavior Are Driven by the CSC Marker DCLK1.
Yu Ikezono; Hironori Koga; Jun Akiba; Mitsuhiko Abe; Takafumi Yoshida; Fumitaka Wada; Toru Nakamura; Hideki Iwamoto; Atsutaka Masuda; Takahiko Sakaue; Hirohisa Yano; Osamu Tsuruta; Takuji Torimura
Molecular cancer research : MCR, Jun. 2017

Pigment Epithelium-Derived Factor (PEDF) Prevents Hepatic Fat Storage, Inflammation, and Fibrosis in Dietary Steatohepatitis of Mice.
Takafumi Yoshida; Jun Akiba; Takanori Matsui; Kazuo Nakamura; Takao Hisamoto; Mitsuhiko Abe; Yu Ikezono; Fumitaka Wada; Hideki Iwamoto; Toru Nakamura; Hironori Koga; Sho-Ichi Yamagishi; Takuji Torimura
Digestive diseases and sciences, Jun. 2017

Effects of in-hospital exercise on liver function, physical ability, and muscle mass during treatment of hepatoma in patients with chronic liver disease.
Shunji Koya; Takumi Kawaguchi; Ryuki Hashida; Emiko Goto; Hiroo Matsuse; Hiromichi Saito; Keisuke Hirota; Ryoko Taira; Yoshiko Matsushita; Minami Imanaga; Ayu Nagamatsu; Tomotake Shirono; Shigeo Shimose; Hideki Iwamoto; Takashi Niizeki; Ryoko Kuromatsu; Hiroko Miura; Naoto Shiba; Takuji Torimura
Hepatology research : the official journal of the Japan Society of Hepatology, Mar. 2017

TCF-4アイソフォームはヒト肝癌細胞においてCLAUDIN-2発現を増強しNOTCHシグナルを活性化する　　　　　　　　　　　　　　　
古賀 浩徳; 和田 史孝; 秋葉 純; 池園 友; 岩本 英希; 中村 徹; 増田 篤高; 阪上 尊彦; 矢野 博久; 鳥村 拓司
日本癌学会総会記事, Oct. 2016

膵神経内分泌腫瘍において癌幹細胞マーカーDCLK1はTyr925FAKを介し、腫瘍増殖・遊走を促進させる　　　　　　　　　　　　　　　
池園 友; 古賀 浩徳; 秋葉 純; 安倍 満彦; 和田 史孝; 中村 徹; 岩本 英希; 増田 篤高; 阪上 尊彦; 矢野 博久; 鳥村 拓司
日本癌学会総会記事, Oct. 2016

xCT-CD44v9システムを標的とするスルファサラジンは、肝癌細胞において酸化ストレスを介したアポトーシスを誘導する　　　　　　　　　　　　　　　
和田 史孝; 古賀 浩徳; 秋葉 純; 池園 友; 中村 徹; 岩本 英希; 阪上 尊彦; 増田 篤高; 安倍 満彦; 矢野 博久; 鳥村 拓司
日本癌学会総会記事, Oct. 2016

進行膵癌患者の癌性腹水中エクソソームにおけるCD133の発現　　　　　　　　　　　　　　　
阪上 尊彦; 古賀 浩徳; 深堀 理; 中村 徹; 池園 友; 和田 史孝; 岩本 英希; 増田 篤高; 鳥村 拓司
日本癌学会総会記事, Oct. 2016

Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study.
Masahito Nakano; Masatoshi Tanaka; Ryoko Kuromatsu; Hiroaki Nagamatsu; Manabu Satani; Takashi Niizeki; Shusuke Okamura; Hideki Iwamoto; Shigeo Shimose; Tomotake Shirono; Yu Noda; Hironori Koga; Takuji Torimura
Oncotarget, 27 Sep. 2016

酸化ストレス抵抗性を標的とした肝癌治療の可能性　　　　　　　　　　　　　　　
和田 史孝; 古賀 浩徳; 秋葉 純; 池園 友; 中村 徹; 岩本 英希; 阪上 尊彦; 増田 篤高; 安倍 満彦; 鹿毛 政義; 矢野 博久; 鳥村 拓司
肝臓, Sep. 2016

Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism.
Yunlong Yang; Yin Zhang; Hideki Iwamoto; Kayoko Hosaka; Takahiro Seki; Patrik Andersson; Sharon Lim; Carina Fischer; Masaki Nakamura; Mitsuhiko Abe; Renhai Cao; Peter Vilhelm Skov; Fang Chen; Xiaoyun Chen; Yongtian Lu; Guohui Nie; Yihai Cao
Nature communications, 01 Sep. 2016

Endothelial PDGF-CC regulates angiogenesis-dependent thermogenesis in beige fat.
Takahiro Seki; Kayoko Hosaka; Sharon Lim; Carina Fischer; Jennifer Honek; Yunlong Yang; Patrik Andersson; Masaki Nakamura; Erik Näslund; Seppo Ylä-Herttuala; Meili Sun; Hideki Iwamoto; Xuri Li; Yizhi Liu; Nilesh J Samani; Yihai Cao
Nature communications, 05 Aug. 2016

Diffusion-weighted magnetic resonance imaging predicts malignant potential in small hepatocellular carcinoma.
Shusuke Okamura; Shuji Sumie; Tatsuyuki Tonan; Masahito Nakano; Manabu Satani; Shigeo Shimose; Tomotake Shirono; Hideki Iwamoto; Hajime Aino; Takashi Niizeki; Nobuyoshi Tajiri; Ryoko Kuromatsu; Koji Okuda; Osamu Nakashima; Takuji Torimura
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, Aug. 2016

Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma.
Takuji Torimura; Hideki Iwamoto; Toru Nakamura; Mitsuhiko Abe; Yu Ikezono; Fumitaka Wada; Takahiko Sakaue; Hiroshi Masuda; Osamu Hashimoto; Hironori Koga; Takato Ueno; Hirohisa Yano
Neoplasia (New York, N.Y.), Jul. 2016

The PDGF-BB-SOX7 axis-modulated IL-33 in pericytes and stromal cells promotes metastasis through tumour-associated macrophages.
Yunlong Yang; Patrik Andersson; Kayoko Hosaka; Yin Zhang; Renhai Cao; Hideki Iwamoto; Xiaojuan Yang; Masaki Nakamura; Jian Wang; Rujie Zhuang; Hiromasa Morikawa; Yuan Xue; Harald Braun; Rudi Beyaert; Nilesh Samani; Susumu Nakae; Emily Hams; Steen Dissing; Padraic G Fallon; Robert Langer; Yihai Cao
Nature communications, 06 May 2016

Hepatic arterial infusion chemoembolization therapy for advanced hepatocellular carcinoma: multicenter phase II study.
Hiroaki Nagamatsu; Shuji Sumie; Takashi Niizeki; Nobuyoshi Tajiri; Hideki Iwamoto; Hajime Aino; Masahito Nakano; Shigeo Shimose; Manabu Satani; Shusuke Okamura; Ryoko Kuromatsu; Satoshi Matsugaki; Junichi Kurogi; Masahiko Kajiwara; Hironori Koga; Takuji Torimura
Cancer chemotherapy and pharmacology, Feb. 2016

Ex vivo expansion of circulating CD34(+) cells enhances the regenerative effect on rat liver cirrhosis.
Toru Nakamura; Hironori Koga; Hideki Iwamoto; Victor Tsutsumi; Yasuko Imamura; Masako Naitou; Atsutaka Masuda; Yu Ikezono; Mitsuhiko Abe; Fumitaka Wada; Takahiko Sakaue; Takato Ueno; Masaaki Ii; Cantas Alev; Atsuhiko Kawamoto; Takayuki Asahara; Takuji Torimura
Molecular therapy. Methods & clinical development, 2016

Successful down-staging of hepatocellular carcinoma with intra-arterial therapy prior to liver transplantation: A case report　　　　　　　　　　　　　　　
Iwamoto H, Nagamatsu H, Niizeki T, Simose S, Sirono T, Koga H, Taketomi A, Kuromatsu R, Torimura T
J Clin Case Rep, Dec. 2015

Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study.
Masahito Nakano; Masatoshi Tanaka; Ryoko Kuromatsu; Hiroaki Nagamatsu; Nobuyoshi Tajiri; Manabu Satani; Takashi Niizeki; Hajime Aino; Shusuke Okamura; Hideki Iwamoto; Shigeo Shimose; Tomotake Shirono; Hironori Koga; Takuji Torimura
Cancer medicine, Dec. 2015

High expression of the putative cancer stem cell marker, DCLK1, in rectal neuroendocrine tumors.
Y U Ikezono; Hironori Koga; Mitsuhiko Abe; Jun Akiba; Akihiko Kawahara; Takafumi Yoshida; Toru Nakamura; Hideki Iwamoto; Hirohisa Yano; Masayoshi Kage; Michio Sata; Osamu Tsuruta; Takuji Torimura
Oncology letters, Oct. 2015

VEGF-B promotes cancer metastasis through a VEGF-A-independent mechanism and serves as a marker of poor prognosis for cancer patients.
Xiaojuan Yang; Yin Zhang; Kayoko Hosaka; Patrik Andersson; Jian Wang; Fredrik Tholander; Ziquan Cao; Hiromasa Morikawa; Jesper Tegnér; Yunlong Yang; Hideki Iwamoto; Sharon Lim; Yihai Cao
Proceedings of the National Academy of Sciences of the United States of America, 02 Jun. 2015

PlGF-induced VEGFR1-dependent vascular remodeling determines opposing antitumor effects and drug resistance to Dll4-Notch inhibitors.
Hideki Iwamoto; Yin Zhang; Takahiro Seki; Yunlong Yang; Masaki Nakamura; Jian Wang; Xiaojuan Yang; Takuji Torimura; Yihai Cao
Science advances, Apr. 2015

Inhibition of hypoxia-inducible factor via upregulation of von Hippel-Lindau protein induces "angiogenic switch off" in a hepatoma mouse model.
Hideki Iwamoto; Toru Nakamura; Hironori Koga; Jesus Izaguirre-Carbonell; Shinji Kamisuki; Fumio Sugawara; Mitsuhiko Abe; Kazuki Iwabata; Yu Ikezono; Takahiko Sakaue; Atsutaka Masuda; Hirohisa Yano; Keisuke Ohta; Masahito Nakano; Shigeo Shimose; Tomotake Shirono; Takuji Torimura
Molecular therapy oncolytics, 2015

Modulation of age-related insulin sensitivity by VEGF-dependent vascular plasticity in adipose tissues.
Jennifer Honek; Takahiro Seki; Hideki Iwamoto; Carina Fischer; Jingrong Li; Sharon Lim; Nilesh J Samani; Jingwu Zang; Yihai Cao
Proceedings of the National Academy of Sciences of the United States of America, 14 Oct. 2014

CD34(+) cell therapy is safe and effective in slowing the decline of hepatic reserve function in patients with decompensated liver cirrhosis.
Toru Nakamura; Takuji Torimura; Hideki Iwamoto; Jyunichi Kurogi; Hiroto Inoue; Yukie Hori; Shuji Sumie; Nobuyoshi Fukushima; Masahiro Sakata; Hironori Koga; Mitsuhiko Abe; Yu Ikezono; Osamu Hashimoto; Takato Ueno; Kazuhiko Oho; Takashi Okamura; Seiya Okuda; Atsuhiko Kawamoto; Masaaki Ii; Takayuki Asahara; Michio Sata
Journal of gastroenterology and hepatology, Oct. 2014

TNFR1 mediates TNF-α-induced tumour lymphangiogenesis and metastasis by modulating VEGF-C-VEGFR3 signalling.
Hong Ji; Renhai Cao; Yunlong Yang; Yin Zhang; Hideki Iwamoto; Sharon Lim; Masaki Nakamura; Patrik Andersson; Jian Wang; Yuping Sun; Steen Dissing; Xia He; Xiaojuan Yang; Yihai Cao
Nature communications, 17 Sep. 2014

Brown adipose tissue, thermogenesis, angiogenesis: pathophysiological aspects.
Jennifer Honek; Sharon Lim; Carina Fischer; Hideki Iwamoto; Takahiro Seki; Yihai Cao
Hormone molecular biology and clinical investigation, Jul. 2014

Methylated-(3'')-epigallocatechin gallate analog suppresses tumor growth in Huh7 hepatoma cells via inhibition of angiogenesis.
Osamu Hashimoto; Anna Nakamura; Toru Nakamura; Hideki Iwamoto; Masuda Hiroshi; Kinya Inoue; Takuji Torimura; Takato Ueno; Michio Sata
Nutrition and cancer, 2014

Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues.
Yunlong Yang; Yin Zhang; Ziquan Cao; Hong Ji; Xiaojuan Yang; Hideki Iwamoto; Eric Wahlberg; Toste Länne; Baocun Sun; Yihai Cao
Proceedings of the National Academy of Sciences of the United States of America, 16 Jul. 2013

Transplantation of endothelial progenitor cells ameliorates vascular dysfunction and portal hypertension in carbon tetrachloride-induced rat liver cirrhotic model.
Masaharu Sakamoto; Toru Nakamura; Takuji Torimura; Hideki Iwamoto; Hiroshi Masuda; Hironori Koga; Mitsuhiko Abe; Osamu Hashimoto; Takato Ueno; Michio Sata
Journal of gastroenterology and hepatology, Jan. 2013

Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma.
Masahito Nakano; Masatoshi Tanaka; Ryoko Kuromatsu; Hiroaki Nagamatsu; Kenji Sakata; Satoru Matsugaki; Masahiko Kajiwara; Kunitaka Fukuizumi; Nobuyoshi Tajiri; Norito Matsukuma; Terufumi Sakai; Noriyuki Ono; Yoichi Yano; Hironori Koga; Junichi Kurogi; Akio Takata; Shuji Sumie; Manabu Satani; Shingo Yamada; Takashi Niizeki; Hajime Aino; Hideki Iwamoto; Takuji Torimura; Michio Sata
Oncology, 2013

Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma.
Takuji Torimura; Hideki Iwamoto; Toru Nakamura; Hironori Koga; Takato Ueno; Robert S Kerbel; Michio Sata
Translational oncology, 2013

Vandetanib, an inhibitor of VEGF receptor-2 and EGF receptor, suppresses tumor development and improves prognosis of liver cancer in mice.
Kinya Inoue; Takuji Torimura; Toru Nakamura; Hideki Iwamoto; Hiroshi Masuda; Mitsuhiko Abe; Osamu Hashimoto; Hironori Koga; Takato Ueno; Hirohisa Yano; Michio Sata
Clinical cancer research : an official journal of the American Association for Cancer Research, 15 Jul. 2012

Prevention of liver fibrosis and liver reconstitution of DMN-treated rat liver by transplanted EPCs.
Toru Nakamura; Takuji Torimura; Hideki Iwamoto; Hiroshi Masuda; Masako Naitou; Hironori Koga; Mitsuhiko Abe; Osamu Hashimoto; Victor Tsutsumi; Takato Ueno; Michio Sata
European journal of clinical investigation, Jul. 2012

Hepatitis C virus core protein upregulates the expression of vascular endothelial growth factor via the nuclear factor-κB/hypoxia-inducible factor-1α axis under hypoxic conditions.
Mitsuhiko Abe; Hironori Koga; Takafumi Yoshida; Hiroshi Masuda; Hideki Iwamoto; Masahiro Sakata; Shinichiro Hanada; Toru Nakamura; Eitaro Taniguchi; Takumi Kawaguchi; Hirohisa Yano; Takuji Torimura; Takato Ueno; Michio Sata
Hepatology research : the official journal of the Japan Society of Hepatology, Jun. 2012

Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy.
Takashi Niizeki; Shuji Sumie; Takuji Torimura; Junichi Kurogi; Ryoko Kuromatsu; Hideki Iwamoto; Hajime Aino; Masahito Nakano; Atsushi Kawaguchi; Tatsuyuki Kakuma; Michio Sata
Journal of gastroenterology, Jun. 2012

Human peripheral blood CD34-positive cells enhance therapeutic regeneration of chronically injured liver in nude rats.
Toru Nakamura; Victor Tsutsumi; Takuji Torimura; Masako Naitou; Hideki Iwamoto; Hiroshi Masuda; Osamu Hashimoto; Hironori Koga; Mitsuhiko Abe; Masaaki Ii; Atsuhiko Kawamoto; Takayuki Asahara; Takato Ueno; Michio Sata
Journal of cellular physiology, Apr. 2012

Interaction of endothelial progenitor cells expressing cytosine deaminase in tumor tissues and 5-fluorocytosine administration suppresses growth of 5-fluorouracil-sensitive liver cancer in mice.
Takuji Torimura; Takato Ueno; Eitaro Taniguchi; Hiroshi Masuda; Hideki Iwamoto; Toru Nakamura; Kinya Inoue; Osamu Hashimoto; Mitsuhiko Abe; Hironori Koga; Vincenza Barresi; Emi Nakashima; Hirohisa Yano; Michio Sata
Cancer science, Mar. 2012

Adiponectin suppresses endoplasmic reticulum stress in nonalcoholic steatohepatitis.
Takato Ueno; Anna Nakamura; Hitomi Nakayama; Shuichi Otabe; Xiaohong Yuan; Tomoka Fukutani; Hideki Iwamoto; Toru Nakamura; Hironori Koga; Takuji Torimura; Michio Sata; Kentaro Yamada
Experimental and therapeutic medicine, Nov. 2011

Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma.
Hideki Iwamoto; Takuji Torimura; Toru Nakamura; Osamu Hashimoto; Kinya Inoue; Junichi Kurogi; Takashi Niizeki; Reiichiro Kuwahara; Mitsuhiko Abe; Hiromori Koga; Hirohisa Yano; Robert S Kerbel; Takato Ueno; Michio Sata
Neoplasia (New York, N.Y.), Mar. 2011

Recent progress in the management of hepatocellular carcinoma detected during a surveillance program in Japan.
Masahito Nakano; Eiji Ando; Ryoko Kuromatsu; Takuji Torimura; Shuji Sumie; Akio Takata; Nobuyoshi Fukushima; Junichi Kurogi; Takashi Niizeki; Hideki Iwamoto; Masatoshi Tanaka; Michio Sata
Hepatology research : the official journal of the Japan Society of Hepatology, Oct. 2010

HCC develops even in the early stage of chronic liver disease in elderly patients with HCV infection.
Akio Takata; Ryoko Kuromatsu; Eiji Ando; Hideki Iwamoto; Nobuyoshi Fukushima; Shuuji Sumie; Takuji Torimura; Michio Sata
International journal of molecular medicine, Aug. 2010

Human primary cultured hepatic stellate cells can be cryopreserved.
Anna Nakamura; Takato Ueno; Yumihiko Yagi; Koji Okuda; Toshiro Ogata; Toru Nakamura; Takuji Torimura; Hideki Iwamoto; Sivakumar Ramadoss; Michio Sata; Victor Tsutsumi; Kaori Yasuda; Yumi Tomiyasu; Kenichi Obayashi; Kosuke Tashiro; Satoru Kuhara
Medical molecular morphology, Jun. 2010

Excellent outcomes with angiographic subsegmentectomy in the treatment of typical hepatocellular carcinoma: a retrospective study of local recurrence and long-term survival rates in 120 patients with hepatocellular carcinoma.
Shozo Iwamoto; Taizo Yamaguchi; Osamu Hongo; Hideki Iwamoto; Hayato Sanefuji
Cancer, 15 Jan. 2010

特集 進行・再発肝細胞癌に対する集学的治療update 8.薬物療法全盛期における肝動注化学療法の役割　　　　　　　　　　　　　　　
岩本英希
肝臓クリニカルアップデート, Oct. 2023

肝細胞癌における従来の分子標的治療薬の問題点と新規血管新生抑制治療の展望　　　　　　　　　　　　　　　
岩本英希、鈴木浩之、古賀浩徳、鳥村拓司
月刊「細胞」The CELL, Feb. 2021

肝細胞癌に対するレンバチニブ治療のバイオマーカー探索および耐性獲得に関与するIGFBP-1についての検討
鈴木浩之; 岩本英希; 中村徹; 増田篤高; 阪上尊彦; 田中俊光; 中野暖; 新関敬; 中野聖士; 岡村修祐; 下瀬茂男; 城野智毅; 野田悠; 蒲池直紀; 黒松亮子; 古賀浩徳; 鳥村拓司
肝臓, 2021

特集:薬物治療がひらく新しい肝細胞癌の治療strategy 3-2:肝細胞癌に対する新規薬物 療法の最新情報(2)アテゾリズマブとベバシズマブ併用の最新情報　　　　　　　　　　　　　　　
岩本英希
臨牀消化器内科, Aug. 2020

STAT3 deficiency prevents hepatocarcinogenesis and promotes transdifferentiation of hepatocytes into biliary cells in chronic liver injury of mice
Mitsuhiko Abe; Takafumi Yoshida; Jun Akiba; Yu Ikezono; Fumitaka Wada; Atsutaka Masuda; Takahiko Sakaue; Toshimitsu Tanaka; Hideki Iwamoto; Toru Nakamura; Sata Michio; Hironori Koga; Akihiko Yoshimura; Takuji Torimura
HEPATOLOGY, Oct. 2017

Oral Session:Medicine:A novel antiangiogenic drug SQAP induces tumor angiogenic swith-off in hepatocellular carcinoma　　　　　　　　　　　　　　　
Iwamoto H, Koga H, Nakamura T, Niizeki T, Shimose S, Shirono T, Kuromatsu R, Yano H, Torimura T
8th EAR Proceedings、A novel antiangiogenic drug SQAP induces tumor angiogenic swith-off in hepatocellular carcinoma, Jan. 2016

肝癌診療マニュアル 第5版　　　　　　　　　　　　　　　
岩本英希; 山内理海; 中川勇人, Joint work, 第5章 肝癌の治療 C 肝癌治療の実際 7.薬物療法：最近の進歩と新しい話題 Ⅰ基礎 e） MTAが肝癌免疫微小環境へ与える影響
医学書院, Apr. 2025
9784260057424

肝癌診療マニュアル 第5版　　　　　　　　　　　　　　　
岩本英希; 永松洋明, Joint work, 第5章 肝癌の治療 C 肝癌治療の実際 4.HAICの適応と成績：最近の進歩と新しい話題 b） New FP療法
医学書院, Apr. 2025
9784260057424

8 肝動注科学療法　　　　　　　　　　　　　　　
岩本英希, Single work
もう迷わない!肝癌薬物療法ナビ、東京, Jun. 2024

Part 3 各論 Systemic chemotherapy不応StageⅣ-B肝細胞癌に対してsorafenibが著効した1症例　　　　　　　　　　　　　　　
岩本英希、永松洋明、鳥村拓司、吉田 博、佐田通夫.工藤正俊 編, Contributor
肝細胞癌の分子標的治療、アークメディア, Aug. 2010

MASLD がデュルマルマブとトレメリムマブ併用療法の治療成績に与える影響―多施設共同研究―　　　　　　　　　　　　　　　
畑中 健; 下瀬茂男; 伊藤隆徳; 佐伯一成; 谷 丈二; 友成 哲; 竹内康人; 佐々木 龍; 佐々木 恭; 本間雄一; 金山雄樹; 長沼 篤; 岩本英希; 大塚基之; 高見太郎; 柿崎 暁
第61回日本肝癌研究会, 11 Jul. 2025

肝細胞癌に対するアテゾリズマブ・ベバシズマブ治療後における ICI 再投与の有効性と安全性：多施設共同研究　　　　　　　　　　　　　　　
伊藤隆徳; 下瀬茂男; 佐伯一成; 竹内康人; 谷 丈二; 友成 哲; 佐々木 龍; 佐々木 恭; 柿崎 暁; 畑中 健; 岩本英希; 山本崇文; 長沼 篤; 宮明寿光; 仁科惣治; 高山哲治; 小原英幹; 大塚基之; 高見太郎; 川嶋哲揮
第61回日本肝癌研究会, 11 Jul. 2025

実臨床における Child B 肝癌に対する Atezolizumab/Bevacizumab 併用療法の治療成績　　　　　　　　　　　　　　　
佐々木 龍; 下瀬茂男; 佐伯一成; 伊藤隆徳; 竹内康人; 谷 丈二; 友成 哲; 佐々木 恭; 柿崎 暁; 畑中 健; 岩本英希; 長沼 篤; 仁科惣治; 高山哲治; 小原英幹; 大塚基之; 川嶋哲揮; 高見太郎; 川口 巧; 宮明寿光
第61回日本肝癌研究会, 10 Jul. 2025

Hepatocellular malignant neoplasm not otherwise specified に肝動注化学療法後conversion 切除した一例　　　　　　　　　　　　　　　
森山悦子; 新関 敬; 岩本英希; 下瀬茂男; 城野智毅; 中野聖士; 黒松亮子; 古賀浩徳; 川口 巧; 秋葉 純; 日比泰造
第61回日本肝癌研究会, 10 Jul. 2025

肝細胞がん患者に対するアテゾリズマブとベバシズマブ併用療法の有効性と腸内細菌叢の関与の検討　　　　　　　　　　　　　　　
城野智毅; 岩本英希; 川口 巧
第61回日本肝臓学会総会, 05 Jun. 2025

1型糖尿病・高脂肪食給餌肝発癌モデルマウスにおけるResmetirom の発がん抑制作用の検討　　　　　　　　　　　　　　　
増田篤高; 中村 徹; 鈴木浩之; 岩本英希; 阪上尊彦; 田中俊光; 古賀浩徳; 川口 巧
第11回肝臓と糖尿病・代謝研究会, 30 May 2025

代謝機能障害関連脂肪肝炎モデルマウスにおけるCD34陽性細胞移植の抗線維化効果と肝発癌への影響　　　　　　　　　　　　　　　
中村 徹; 増田篤高; 鈴木浩之; 岩本英希; 阪上尊彦; 田中俊光; 古賀浩徳; 川口 巧
第11回肝臓と糖尿病・代謝研究会, 30 May 2025

StageIVB肝細胞癌に対しアテゾリズマブ＋ベマシズマブ療法を行ったが急速増大し、NFP療法にて奏効が得られた一例　　　　　　　　　　　　　　　
森山悦子; 城野智毅; 新関 敬; 岩本英希; 下瀬茂男; 鈴木浩之; 中野聖士; 黒松亮子; 古賀浩徳; 川口 巧
第125回日本消化器病学会九州支部例会/第119回日本消化器内視鏡学会九州支部例会, 17 May 2025

Leucine sensing and mTOR activation drive SNAIL-mediated EMT in pancreatic cancer cells　　　　　　　　　　　　　　　
Koga H.; Imamura Y.; Masuda A.; Suzuki H.; Tanaka T.; Sakaue T.; Iwamoto H.; Nakamura T.; Kawaguchi T.
AACR Annual Meeting 2025, 30 Apr. 2025

Development of a diagnostic method for early-stage pancreatic cancer through exosome-derived microRNA profiling　　　　　　　　　　　　　　　
Sakaue T.; Koga H.; Iwamoto H.; Nakamura T.; Masuda A.; Tanaka T.; Suzuki H.; Hara Y.; Saito K.; Shimamatsu Y.; Yoshimura S.; Hirai S.; Terabe H.; Takedatsu H.; Kawaguchi T.
AACR Annual Meeting 2025, 28 Apr. 2025

Atezolizumab+Bevacizumab 併用療法によりconversion surgery を行い得た肝細胞 癌の一例～癌免疫微小環境の免疫染色による評価～　　　　　　　　　　　　　　　
岩本英希、三原勇太郎、古賀浩徳、川口 巧、秋葉 純
第30回日本肝がん分子標的治療研究会, Jul. 2024

Atezolizumab+Bevacizumab併用療法後肝切除標本からみる複合免疫療法による興味深い癌免疫微小環境の変化　　　　　　　　　　　　　　　
岩本英希、三原勇太郎、古賀浩徳、川口 巧
第60回日本肝癌研究会, Jul. 2024

リザーバーカテーテル留置困難症例に対して、コアキシャル留置法の変法で留置し得た進行肝細胞癌の一例　　　　　　　　　　　　　　　
岩本英希、新関 敬、城野智毅、下瀬茂男、森山悦子、川口祐太朗、山口泰三、古賀浩徳、川口 巧
第48回 リザーバー&ポート研究会, Jun. 2024

肝細胞癌に対する複合免疫療法に関する基礎的理論的根拠～ABC conversion,肝動注による免疫誘導,Triplet therapy～　　　　　　　　　　　　　　　
岩本英希、古賀浩徳、川口 巧
第60回日本肝臓学会総会, Jun. 2024

Usefullnes of a novel microcatheter insertable port ReMAP/System-i for transarterial therapy of HCC　　　　　　　　　　　　　　　
Iwamoto H, Itano S, Niizeki T, Shirono T, Kawaguchi T
APASL 2024 Kyoto-The Center of Hepatology, Mar. 2024

肝細胞癌に対するTriple therapy の基礎的Rationale ～抗PD-L1, 抗VEGF, 抗CTLA-4 抗体のシークエンス治療～　　　　　　　　　　　　　　　
岩本英希、鈴木浩之、下瀬茂男、城野智毅、新関 敬、酒井味和、中野聖士、野田 悠、森山悦子、黒松亮子、古賀浩徳、川口 巧
第29回日本肝がん分子標的治療研究会, Jan. 2024

薬物療法全盛期の中におけるNew FP 療法に関する現実的な前向き試験案　　　　　　　　　　　　　　　
岩本英希
第47回 リザーバー&ポート研究会, Nov. 2023

反復的・間欠的経動脈治療を可能とする大動脈留置型特殊リザーバーポートReMAP の有用性の検証　　　　　　　　　　　　　　　
岩本英希
第47回 リザーバー&ポート研究会, Nov. 2023

Importance of preclinical rationales to establish appropriate treatment sequences in the era of chemo-diversity for HCC　　　　　　　　　　　　　　　
Iwamoto H, Koga H, Kawaguchi T
JDDW 2023, Nov. 2023

The Effectiveness of the Locoregional Treatment Using Hepatic Arterial Infusion Chemotherapy New FP for Locally Progressed Hepatocellular Carcinoma　　　　　　　　　　　　　　　
Iwamoto H, Niizeki T, Shimose S, Shirono T, Kawaguchi T
APASL Oncology 2023, Oct. 2023

肝細胞癌における癌血管特異的micro RNA を利用した新規血管新生抑制治療　　　　　　　　　　　　　　　
岩本英希、古賀浩徳、川口 巧
第55回日本臨床分子形態学会総会・学術集会, Sep. 2023

反復的・間欠的経動脈治療を可能とする新規留置カテーテルSystem-i/ReMAP の有用性の検証　　　　　　　　　　　　　　　
岩本英希、板野 哲、川口 巧
第59回日本肝臓学会総会, Jun. 2023

肝癌免疫微小環境　　　　　　　　　　　　　　　
岩本英希、鈴木浩之、古賀浩徳、川口 巧
第54回日本臨床分子形態学会・学術集会, Nov. 2022

Clinical Significance of the Discrepancy Between Radiological Findings and Biochemical Responses in Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma　　　　　　　　　　　　　　　
Iwamoto H, Shimose S, Niizeki T, Shirono T, Suzuki H, Nakano M, Noda Y, Kamachi N, Moriyama E, Kuromatsu R, Koga H and Kawaguchi T
The Liver Meeting Digital Experience 2022(The 73th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)), Nov. 2022

薬物療法時代の中で肝動注化学療法New FP療法をアテゾリズマブ+ベバシズマブ併用療法に先行して導入する事による新たな治療戦略　　　　　　　　　　　　　　　
岩本英希、新関 敬、古賀浩徳
JDDW 2022, Oct. 2022

Hepatic Arterial Infusion Chemotherapy New-FP for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombus - multi-center retrospective analysis-　　　　　　　　　　　　　　　
Iwamoto H
APASL Oncology 2022, Sep. 2022

New FP療法への期待　　　　　　　　　　　　　　　
岩本英希
第6回日本臨床薬理学会 九州・沖縄地方会, Jul. 2022

ガイドラインで引用される論文とは　　　　　　　　　　　　　　　
岩本英希
第58回日本肝臓学会総会, Jun. 2022

肝細胞癌のレンバチニブ薬剤耐性における癌微小環境の関わり～癌線維芽細胞の重要性～　　　　　　　　　　　　　　　
岩本英希、古賀浩徳、鳥村拓司
第58回日本肝臓学会総会, Jun. 2022

肝細胞癌のレンバチニブ薬剤耐性における癌線維芽細胞の HGF-cMET シグナルの重要性　　　　　　　　　　　　　　　
岩本英希、古賀浩徳、鳥村拓司
第108回日本消化器病学会総会, Apr. 2022

Internmediate stage HCC (TKI Lenvatinib) Importance of keeping balance between therapeutic effects and adverse events in lenvatinib for hepatocellular carcinoma　　　　　　　　　　　　　　　
Iwamoto H
APASL Oncology 2021, Dec. 2021

シンポジウム(10)がん微小環境と肝細胞癌の発癌・進展機構 肝細胞癌における分子標的治療薬によるがん微小環境の変化と役割　　　　　　　　　　　　　　　
岩本英希、鳥村拓司
第44回日本肝臓学会西部会, Dec. 2021

Initial experience of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in real-world clinical practice　　　　　　　　　　　　　　　
Iwamoto H, Shimose S, Takashi N, Noda Y, Shirono T, Nakano M, Okamura S, Kamachi N, Suzuki H, Kuromatsu R, Koga H and Torimura T
The Liver Meeting Digital Experience 2021(The 72th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)), Nov. 2021

The effectiveness of the locoregional treatment using hepatic arterial infusion chemotherapy for locally progressed hepatocellular carcinoma　　　　　　　　　　　　　　　
Iwamoto H, Koga H, Torimura T
29th JDDW(第25回日本肝臓学会大会・第63回日本消化器病学会大会・第19回日本消化器外科学会大会), Nov. 2021

Workshop(Ⅱ)The New Talent Workshop(Breakthrough basic researches in HCC for newly developed molecular and immune targeted therapies) Novel anti-angiogenic therapy using tumor endothelial cell-specific microRNA in hepatocellular carcinoma　　　　　　　　　　　　　　　
Iwamoto H, Suzuki H, Koga H, Torimura T
JSH International Liver Conference 2021, Oct. 2021

多剤MTA時代における各々のMTAによる特有の癌微小環境の変化の理解　　　　　　　　　　　　　　　
岩本英希、鈴木浩之、古賀浩徳、鳥村拓司
第28回肝細胞研究会, Sep. 2021

切除不能進行肝細胞癌に対するアテゾリズマブ+ベバシズマブ併用療法のreal worldデータを用いた初期使用経験-多施設後ろ向き解析-　　　　　　　　　　　　　　　
岩本英希、下瀬茂男、城野智毅、野田 悠、岡村修祐、蒲池直紀、鈴木浩之、黒松亮子、新関 敬、古賀浩徳、鳥村拓司
第24回日本肝がん分子標的治療研究会, Aug. 2021

シンポジウム(1)複合免疫療法時代を迎えた新たな進行肝癌治療 肝細胞癌に対するアテゾリズマブ+ベバシズマブ併用療法の多施設後ろ向き Real-worldデータ解析　　　　　　　　　　　　　　　
岩本英希、下瀬茂男、野田 悠、城野智毅、中野聖士、新関 敬、岡村修祐、蒲池直紀、鈴木浩之、黒松亮子、古賀浩徳、鳥村拓司
第57回日本肝癌研究会, Jul. 2021

Intermediate stage HCC治療にTACE と薬物療法をどう組み込むか　　　　　　　　　　　　　　　
岩本英希
日本IVR学会・肝動脈塞栓療法研究会2021 学会リポート, Jun. 2021

ワ-クショップ(10)肝臓研究の frontline 肝細胞癌における癌血管特異的 micro RNA を利用した新規血管新生抑制治療　　　　　　　　　　　　　　　
岩本英希、古賀浩徳、鳥村拓司
第57回日本肝臓学会総会, Jun. 2021

パネルディスカッション(6)進行肝癌の薬物療法の臨床成績と問題点 肝細胞癌に対する肝動注化学療法 New FP 療法とソラフェニブの治療成績の多施設後ろ向き比較研究　　　　　　　　　　　　　　　
岩本英希、古賀浩徳、鳥村拓司
第57回日本肝臓学会総会, Jun. 2021

シンポジウム Intermediate-stage HCCに対する治療戦略:TACEと薬物療法の立ち位置は??薬物療法全盛期を迎えて Intermediate HCC における腫瘍の拡がりの重要性と TACE-MTA の集学的治療　　　　　　　　　　　　　　　
岩本英希
第26回肝動脈塞栓療法研究会, May 2021

シンポジウム(4)肝疾患と微小環境 分子標的治療薬による癌及び臓器微小環境の変化は、有害事象の出現や癌の進展及び薬剤抵抗性に関与しうる　　　　　　　　　　　　　　　
岩本英希、古賀浩徳、鳥村拓司
第56回日本肝臓学会総会, Aug. 2020

ワ-クショップ(6) 臨床応用に向けた肝癌の病態解明 肝細胞癌に対する血管新生阻害剤の正常臓器血管への影響と癌血管特異的遺伝子の探索　　　　　　　　　　　　　　　
岩本英希、古賀浩徳、鳥村拓司
第106回日本消化器病学会総会, Aug. 2020

肝細胞癌に対するレンバチニブ投与における有害事象出現時期と外来テレフォンフォローアップの重要性について　　　　　　　　　　　　　　　
岩本英希、下瀬茂男、新関 敬、津村紗代、中野聖士、城野智毅、山口泰三、田中正俊、古賀浩徳、鳥村拓司
第21回日本肝がん分子標的治療研究会, Jan. 2020

シンポジウム(5) 次世代シークエンサを用いたゲノム解析による肝疾患研究 非癌部肝組織のDNAメチル化の変化は肝細胞癌の多中心性発生のバイオマーカーになり得る　　　　　　　　　　　　　　　
岩本英希、古賀浩徳、鳥村拓司
第42回日本肝臓学会東部会, Dec. 2018

肝細胞癌に対する血管新生阻害剤の正常臓器血管への影響と癌血管特異的遺伝子の探索　　　　　　　　　　　　　　　
岩本英希、古賀浩徳、鳥村拓司
26th JDDW(第22回日本肝臓学会大会), Nov. 2018

Fatty Liver Environment Confers Antiangiogenic Drug Resistance to Hepatocellular Carcinoma and Metastatic Liver Cancer of Colorectal Cancer through Activation of Lipid Dependent Metabolic Pathway　　　　　　　　　　　　　　　
Iwamoto H, Abe M, Koga H, Cao Y and Torimura T
The 69th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Nov. 2018

Multicenter Retrospective Study of New FP, a Novel Regimens of Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Major Macrovascular Invasion　　　　　　　　　　　　　　　
Iwamoto H, Niizeki T, Nagamatsu H, Shimose S, Shirono T, Tanaka M, Yamaguchi T, Koga H and Torimura T
The 69th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Nov. 2018

高度脈管侵襲を伴う進行肝細胞癌に対するNew FP療法の意義　　　　　　　　　　　　　　　
岩本英希
第43回リザーバー研究会, Aug. 2018

共催シンポジウム(2)レンバチニブがもたらす新たな治療アプ ローチ 基礎と臨床から見る肝細胞癌に対する分子標的治療薬不応後の治療戦略　　　　　　　　　　　　　　　
岩本英希、中野聖士、新関 敬、下瀬茂男、城野智毅、田中正俊、古賀浩徳、鳥村拓司
第18回日本肝がん分子標的治療研究会, Jul. 2018

癌周囲の高脂肪環境は癌のエネルギー代謝のリプログラミングを介し,血管新生阻害剤耐性を産み出　　　　　　　　　　　　　　　
岩本英希、安倍満彦、鳥村拓司
第54回日本肝臓学会総会, Jun. 2018

シンポジウム(2) 肝癌治療の最新の試み 高度脈管侵襲を有するStage IVa進行肝細胞癌に対する肝動注化学療法 New FP療法の治療成績の多施設後ろ向き研究　　　　　　　　　　　　　　　
岩本英希、新関 敬、永松洋明、山口泰三、古賀浩徳、鳥村拓司
第111回日本消化器病学会九州支部例会、第105回日本消化器内視鏡学会九州支部例会 合同, Jun. 2018

Antiangiogenesis-triggered lipiddependent metabolic reprograming confers drug resistance to cancer cells　　　　　　　　　　　　　　　
Iwamoto H
APASL Single Topic Conference on HCC Yokohama Japan, May 2018

脈管浸潤を伴う進行肝細胞癌に対するNew-FP療法と放射線治療の併用療法についての検討　　　　　　　　　　　　　　　
岩本英希、新関 敬、下瀬茂男、城野智毅、相野 一、中野聖士、佐谷 学、岡村修祐、野田 悠、黒松亮子、古賀浩徳、鳥村拓司
25th JDDW(第21回日本肝臓学会大会), Oct. 2017

非癌部肝組織のDNAメチル化の変化は肝細胞癌の多中心性発生のバイオマーカーになり得る　　　　　　　　　　　　　　　
岩本英希、古賀浩徳、山本 健、鳥村拓司
25th JDDW(第59回日本消化器病学会大会), Oct. 2017

Inhibition of hypoxia inducible factor via upregulation of von Hippel-Lindau protein induces ‘Angiogenic switch off’ in a mouse hepatoma model　　　　　　　　　　　　　　　
Iwamoto H,, Koga H, Torimura T
The 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Oct. 2017

血液透析中に発症した門脈腫瘍栓を伴う進行肝細胞癌に肝動注化学療法が奏功し、肝切除を加え完全奏効となった1例　　　　　　　　　　　　　　　
岩本英希、新関 敬、相野 一、下瀬茂男、城野智毅、古賀浩徳、鳥村拓司
第42回リザーバー研究会, Sep. 2017

(特別企画)リザーバー動注化学療法のいままでそしてこれから:動注化学療法のエビデンス:肝細胞癌　　　　　　　　　　　　　　　
岩本英希
第42回リザーバー研究会, Sep. 2017

脈管浸潤を伴う進行肝細胞癌に対する放射線治療の有効性について　　　　　　　　　　　　　　　
岩本英希、新関 敬、下瀬茂男、城野智毅、中野聖士、佐谷 学、岡村修祐、野田 悠、黒松亮子、古賀浩徳、鳥村拓司
第53回日本肝癌研究会, Jul. 2017

血管新生抑制剤の中止は肝類洞のRevascularizationを引き起こす　　　　　　　　　　　　　　　
岩本英希、古賀浩徳、鳥村拓司
第53回日本肝臓学会総会, Jun. 2017

シンポジウム(1)消化器癌診療への基礎研究からみたアプローチ:血管新生阻害剤の中断は正常肝の血管構造の変化により癌の転移を促進する　　　　　　　　　　　　　　　
岩本英希、安倍満彦、中野聖士、古賀浩徳、鳥村拓司
第109回日本消化器病学会九州支部例会、第103回日本消化器内視鏡学会九州支部例会 合同, May 2017

共催シンポジウム(2)ソラフェニブ治療の現状と課題:進行肝細胞癌403例に対するソラフェニブの効果についての検証と血管新生阻害剤中断後におこる病態についての基礎的な検証　　　　　　　　　　　　　　　
岩本英希、中野聖士、新関 敬、古賀浩徳、Yihai Cao、鳥村拓司
第15回日本肝がん分子標的治療研究会, Jan. 2017

ワークショップ(7)脈管侵襲を伴わない多結節肝細胞癌に対する治療戦略　　　　　　　　　　　　　　　
岩本英希、古賀浩徳、鳥村拓司
第52回日本肝癌研究会, Jul. 2016

肝細胞癌に対する新規血管新生阻害剤SQAPの有するユニークな血管新生阻害効果:Angiogenic Switch Off　　　　　　　　　　　　　　　
岩本英希、中野聖士、中村 徹、古賀浩徳、池園 友、和田史孝、増田 裕、阪上尊彦、下瀬茂男、城野智毅、新関 敬、黒松亮子、鳥村拓司
第14回日本肝がん分子標的治療研究会, Jun. 2016

マウス肝癌モデルを用いたNotch抑制剤の効果検討　　　　　　　　　　　　　　　
岩本英希、鳥村拓司、古賀浩徳
肝臓、第52回日本肝臓学会総会, May 2016

シンポジウム(2)肝細胞癌における血管新生を標的とした分子標的治療の新知見　　　　　　　　　　　　　　　
岩本英希、鳥村拓司
肝臓、第41回日本肝臓学会西部会, Dec. 2015

腫瘍Transglutaminase 2を標的とした新規血管新生阻害剤SQAPの肝細胞癌に対する効果の基礎的検討　　　　　　　　　　　　　　　
岩本英希、中村 徹、古賀浩徳、池園 友、下瀬茂男、相野 一、新関 敬、田尻能祥、黒松亮子、鳥村拓司
肝臓、23rd JDDW(第19回日本肝臓学会大会), Oct. 2015

シンポジウム(2)肝癌における血管新生の重要性　　　　　　　　　　　　　　　
岩本英希、古賀浩徳、鳥村拓司
第47回日本臨床分子形態学会総会・学術集会, Sep. 2015

腫瘍von Hippel Lindau蛋白を標的とした新規血管新生阻害剤SQAPの肝細胞癌に対する効果の基礎的検討　　　　　　　　　　　　　　　
岩本英希、中村 徹、安倍満彦、池園 友、和田史孝、黒松亮子、田尻能祥、矢野博久、古賀浩徳、鳥村拓司
肝臓、第51回日本肝臓学会総会, May 2015

Poster Area:A novel synthetic sulfoglycolipid sulfoqunovosylacyl-propanediol (SQAP) switches off tumor angiogenic potential of hepatocellular carcinoma through the upregulation of von hippel-lindau protein　　　　　　　　　　　　　　　
Iwamoto H, Torimura T, Ohta K, Koga H, Nakamura T, Abe M, Masuda H, Yano H, Sata M
Journal of Hepatology、48th Annual Meeting of the European Association for the Study of the Liver (EASL), Apr. 2013

肝細胞癌におけるS-1 metronomic chemotherapyとvandetanib併用療法の効果と安全性の硬化と安全性の検討　　　　　　　　　　　　　　　
岩本英希、鳥村拓司、佐田通夫
第47回日本肝癌研究会, Jul. 2011

肝細胞癌に対するソラフェニブの治療効果と副作用:多施設での検討　　　　　　　　　　　　　　　
岩本英希、中野聖士、佐田通夫
第3回日本肝がん分子標的治療研究会, Jan. 2011

Effect of metronomic chemotherapy with S-1 + vandetanib in a mouse model of hepatocellular carcinoma　　　　　　　　　　　　　　　
Hideki Iwamoto, Takuji Torimura, Toru Nakamura, Hirohisa Yano, Takato Ueno, Michio Sata
Hepatology、The 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Oct. 2010

遠隔転移を有する進行肝細胞癌に対する治療成績　　　　　　　　　　　　　　　
岩本英希、永松洋明、鳥村拓司、黒木淳一、新関 敬、相野 一、中野聖士
肝臓、18th JDDW(第14回日本肝臓学会大会), Oct. 2010

肝細胞癌におけるS-1を用いたメトロノミックケモセラピーとvandetanib併用の有効性検討:血管新生抑制による抗腫瘍効果　　　　　　　　　　　　　　　
岩本英希、鳥村拓司、佐田通夫
肝臓、18th JDDW(第52回日本消化器病学会大会、第14回日本肝臓学会大会 合同), Oct. 2010

肝細胞癌に対するS-1を用いたmetronomic hemotherapyとvandetanibの併用療法　　　　　　　　　　　　　　　
岩本英希、鳥村拓司、橋本 修、上野隆登、矢野博久、佐田通夫
第69回日本癌学会学術総会, Sep. 2010

Metronomic chemotherapy of S-1 and vandetanib:an efficacious and non-toxic treatment for hepatocellular carcinoma　　　　　　　　　　　　　　　
Hideki Iwamoto, Takuji Torimura, Takato Ueno, R.Kerbel, Michio Sata
4th ILCA Annual Conference, Sep. 2010

肝細胞癌におけるS-1を用いたmetronomic chemotherapyとvandetanibの併用効果の検討　　　　　　　　　　　　　　　
岩本英希、鳥村拓司、中村 徹、黒木淳一、新関 敬、相野 一、黒松亮子、高田晃男、住江修治、佐谷 学、中野聖士、矢野博久、上野隆登、佐田通夫
第12回筑後地区肝胆膵研究会, Jul. 2010

問題症例検討(4)治療 症例　　　　　　　　　　　　　　　
岩本英希、永松洋明、武富紹信、黒木淳一、新関 敬、相野 一、中野聖士、黒松亮子、高田晃男、住江修治、佐谷 学、鳥村拓司、吉田 博、副島雄二、佐田通夫
第46回日本肝癌研究会, Jul. 2010

肝細胞癌におけるTS-1を用いたメトロノミックケモセラピーの検討とVandetanib併用による作用増強効果の検討　　　　　　　　　　　　　　　
岩本英希、鳥村拓司、中村 徹、黒木淳一、新関 敬、相野 一、黒松亮子、高田晃男、住江修治、佐谷 学、中野聖士、矢野博久、上野隆登、佐田通夫
肝臓、第46回日本肝臓学会総会, May 2010

Low dose metronomic chemotherapy of S-1 and Vandetanib produces nontoxically good therapeutic results for hepatocellular carcinoma (HCC)　　　　　　　　　　　　　　　
Iwamoto Hideki, Takuji Torimura, Toru Nakamura, Takato Ueno, Hirohisa Yano, Michio Sata
The 101st Annual Meeting of the American Association for Cancer Research (AACR), Apr. 2010

肝細胞癌におけるTS-1を用いたメトロノミックケモセラピーとVandetanib併用効果の検討　　　　　　　　　　　　　　　
岩本英希、鳥村拓司、中村 徹、黒木淳一、新関 敬、相野 一、黒松亮子、高田晃男、住江修治、佐谷 学、中野聖士、上野隆登、佐田通夫
第1回日本肝がん分子標的治療研究会, Jan. 2010

右房内腫瘍栓、門脈本幹腫瘍栓を伴う進行肝細胞癌にRadiation併用下New FP療法を行い病勢コントロールし得た1例　　　　　　　　　　　　　　　
岩本英希、永松洋明、水上直久、黒木淳一、新関 敬、板野 哲、鳥村拓司、佐田通夫
第34回リザーバー研究会, Oct. 2009

単結節周囲増殖型及び多結節癒合型肝細胞癌に対する治療法の比較検討　　　　　　　　　　　　　　　
岩本英希、永松洋明、平成 守、黒木淳一、黒松亮子、井上欣哉、新関 敬、高田晃男、福嶋伸良、住江修治、中野聖士、鳥村拓司、吉田 博、佐田通夫
肝臓、17th JDDW(第13回日本肝臓学会大会), Oct. 2009

症例　　　　　　　　　　　　　　　
岩本英希、永松洋明、板野 哲、水上直久、新関 敬、高田晃男、黒木淳一、鳥村拓司、佐田通夫
第45回日本肝癌研究会, Jul. 2009

初発肝細胞癌根治治療から、2年の無再発期間を経て肺転移再発を来たした脾臓摘出術後B型肝硬変症の1例　　　　　　　　　　　　　　　
岩本英希、安東栄治、黒木淳一、黒松亮子、長岡 栄、高田晃男、福嶋伸良、井上欣哉、新関 敬、鳥村拓司、佐田通夫
第44回日本肝癌研究会, May 2008

肝予備能の低下した巨大肝細胞癌症例に対する大動脈留置型特殊リザーバー(System-I-2)を用いた治療の工夫　　　　　　　　　　　　　　　
岩本英希、板野 哲、久富順次郎、佐田通夫
第32回リザーバー研究会, Jan. 2008

出血をきたした小腸 inflammatory fibroid polyp の1例　　　　　　　　　　　　　　　
岩本英希、河野弘志、鶴田 修、澤 優子、桑木光太郎、吉森建一、唐原 健、中原慶太、居石哲治、光山慶一、佐田通夫、豊永 純
第89回日本消化器病学会九州支部例会、第83回日本消化器内視鏡学会九州支部例会 合同, Jun. 2007

DNA methylation level of 10 CpG sites on 8 specific genes in non-cancerous liver tissues is useful to predict multicentric recurrence of hepatocellular carcinoma after surgical resection
Grant-in-Aid for Scientific Research (C)
Kurume University
01 Apr. 2016 - 31 Mar. 2019